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Repression of many tumor suppressor genes (TSGs) in cancer is mediated by 
aberrantly increased DNA methylation levels at promoter CpG islands (CGI). About 
one-fourth of empirically defined human promoters are surrounded by or contain 
clustered repetitive elements. It was previously observed that a sharp transition of 
methylation occurs between highly methylated repetitive elements (SINE or LINE) and 
unmethylated CGI-promoters (e.g. P16, VHL, CDH and RIL) in normal tissues. The 
functions that lead to increased CGI methylation in cancer remain poorly understood. 
We propose that CGI-promoters contain cis-elements for triggering de novo DNA 
methylation. In the first part of our project, we established a site-specific integration 
system with enforced local transcriptional repression in colorectal cancer cells and 
monitored the occurrence of de novo DNA methylation in exogenous fragments 
containing a CGI-promoter and repetitive elements. Initial de novo methylation was 
seeded at specific CG sites in a repetitive element, and accelerated by persistent binding 
vi 
 
of a KRAB-containing transcriptional repressor. Furthermore, additional repetitive 
elements (LINE and SINE) located adjacent to the promoter could confer DNA 
methylation spreading into the CGI particularly in the setting of KRAB-factor binding. 
However, a repressive chromatin alone was not sufficient to initiate DNA methylation, 
which required specific DNA sequences and was integration-site (and/or cell-line) 
specific. In addition, all the methylation observed showed slow and gradual 
accumulation over several months of culture. Overall, these results demonstrate a 
requirement for specific DNA sequences to trigger de novo DNA methylation, and 
repetitive elements as cis-regulatory factors to cooperate with strengthened 
transcriptional repression in promoting methylation spreading. In the second part, we 
re-introduced disrupted DNMT3B or DNMT1 into HCT116 DKO cells and mapped the 
remethylation pattern through a profiling method (DREAM). Moderate remethylation 
occurred when DNMT3B was re-expressed with a preference toward non-CGI and non-
promoter regions. Hence, there exists a set of genomic regions with priority to be targets 
for DNMT3B in somatic cells. 
  
vii 
 
Table of Contents 
Approval sheet ................................................................................................................. i 
Title page ......................................................................................................................... ii 
Dedication ....................................................................................................................... iii 
Acknowledgments .......................................................................................................... iv 
Abstract ........................................................................................................................... v 
Table of Contents .......................................................................................................... vii 
List of figures .................................................................................................................. xi 
List of tables .................................................................................................................. xv 
Chapter 1 
Introduction ................................................................................................................. 1 
Cytosine methylation in normal mammalian cells  ................................................... 1 
Basic functions of DNA methyltransferases  ............................................................ 1 
DNA methylation reprogramming during development  .......................................... 7 
DNA methylation changes in cancer  ........................................................................ 9 
Recognition of methylation signals  ........................................................................ 11 
Epigenetic loop of transcriptional repression  ......................................................... 14 
DNA methylation spreading and protection  ........................................................... 15 
Methylation center definition  ................................................................................. 17 
Components in controlling DNA methylation — transcriptionally repressive 
histone signatures and their modifiers  .................................................................... 19 
Components in controlling DNA methylation — chromatin remodeling factors and 
nucleosomes  ........................................................................................................... 21 
Components in controlling DNA methylation — small RNAs and long non-coding 
RNAs  ...................................................................................................................... 21 
Genome-wide methylation profiling approaches (next-generation sequencing)  ... 24 
Hypothesis and specific aims .................................................................................... 27 
 
Chapter 2 
Methods and materials ............................................................................................. 30 
Human samples ....................................................................................................... 30 
Cell culture .............................................................................................................. 30 
viii 
 
DNA extraction and bisulfite conversion ................................................................ 30 
PCR, cloning and DNA sequencing (Bisulfite cloning/sequencing) ...................... 31 
Bisulfite pyrosequencing ......................................................................................... 31 
RNA extraction and Quantitative RT-PCR ............................................................. 43 
Generation of stable single clones with single integration sites .............................. 43 
β-Gal Staining ......................................................................................................... 44 
Inverse PCR ............................................................................................................. 44 
Establishment of Flpin-tTS host cells ..................................................................... 44 
Flow cytometry ....................................................................................................... 44 
Construction of transgenes, homologous recombination and clonal selection  ...... 45 
Drug treatment  ........................................................................................................ 45 
ChIP analysis  .......................................................................................................... 46 
Protein extraction and western blot  ........................................................................ 46 
DREAM library preparation  ................................................................................... 47 
DREAM library validation — Pyrosequencing and TA cloning  ........................... 48 
Data processing and statistics .................................................................................. 48 
 
Chapter 3 
Establish a site-specific integration system with enforced transcriptional 
repression ....................................................................................................................... 49 
Introduction ............................................................................................................... 49 
Results ........................................................................................................................ 51 
Construction of flp-in host cells .............................................................................. 51 
Heterochromatic environment of the insertion sites ............................................... 59 
Generation of flp-in/tTS host cells .......................................................................... 60 
Discussion ................................................................................................................... 65 
 
Chapter 4 
Repetitive elements and strengthened local heterochromatin enhanced de novo 
methylation in a promoter-CGI  ................................................................................. 68 
Introduction ............................................................................................................... 68 
Results ........................................................................................................................ 70 
ix 
 
Mapping the methylation patterns of RIL (PDLIM4) promoter ............................. 70 
Construction of transgenes ...................................................................................... 73 
Continuous culturing under selection pressure populated unmethylated clones ..... 77 
Unequal silencing speeds of transgenes in flp-in and flp-in/tTS cells .................... 77 
De novo DNA methylation center in transgenes ..................................................... 78 
The effects of repetitive elements on DNA methylation spreading ........................ 86 
Gradual accumulation of methylated cytosine over time ........................................ 86 
Long-distance spreading was not direction-dependent ........................................... 87 
Promoted CGI methylation arose from adjacent de novo methylation ................... 88 
A highly repressive environment can enhance de novo methylation and methylation 
spreading ................................................................................................................. 91 
Local heterochromatin in transgenes ....................................................................... 92 
The presence of tTS made trasgenes refractory to TSA-induced derepression ...... 97 
The effects of cell lines or genomic loci on DNA methylation recruitment ........... 97 
Discussion ................................................................................................................. 102 
 
Chapter 5 
The de novo methylation in somatic cells caused by re-expressing DNMT3B in a 
genetically engineered model ..................................................................................... 107 
Introduction ............................................................................................................. 107 
Results ...................................................................................................................... 108 
Methylation is not equally recovered in DKO cells .............................................. 108 
Re-expression of DNMT3B or DNMT1 moderately recovered global DNA 
methylation ............................................................................................................ 117 
Preferential representation of CGI methylation for DREAM ............................... 117 
Re-expressed DNMT3B favored non-CGIs .......................................................... 119 
Promoters were more resistant to re-expressed DNMT3B ................................... 120 
Discussion ................................................................................................................. 134 
 
Conclusions .................................................................................................................. 137 
Significance and future directions ............................................................................. 140 
References .................................................................................................................... 144 
x 
 
Vita ............................................................................................................................... 164 
 
  
xi 
 
List of figures 
Chapter 1 
Figure 1. Structural overview of the functional domains of the DNA methyltransferase 
family.. .............................................................................................................................. 4 
Figure 2. A proposed model for the maintenance of DNA methylation in mammalian 
cells. .................................................................................................................................. 6 
Figure 3. Reprogramming of DNA methylation during early development in mammals..
 .......................................................................................................................................... 8 
Figure 4. The model for the feedback loop of epigenetic regulations. ........................... 13 
Figure 5. The model of "methylation center" and protection around the CpG-promoter.
 ........................................................................................................................................ 23 
Figure 6. Profiling DNA methylation by DREAM analysis. .......................................... 26 
Chapter 2 
Figure 7. Schematic description of establishing a site-specific integration system.. ..... 53 
Figure 8. Transfection of pFRT/LacZeo into cell lines.. ................................................ 54 
Figure 9. Tiling primers to screen out possible single clones with single integration 
sites.. ............................................................................................................................... 55 
Figure 10. Identify and validate the single integration site of flp-in host cells. (A) 
Graphical description of inverse PCR.. .......................................................................... 57 
Figure 11. DNA methylation of the environment for homologous recombination.. ...... 61 
Figure 12. Chromatin signatures of the integration sites in SW48 and HCT116.. ......... 62 
Figure 13. Generation of flp-in/tTS host cells. ............................................................... 64 
 
xii 
 
Chapter 3 
Figure 14. Mapping the methylation pattern of RIL promoter by bisulfite sequencing..72 
Figure 15. Construction of trangenes. ............................................................................. 75 
Figure 16. Continuous selection populated unmethylated clones.. ................................ 76 
Figure 17. Unequal GFP silencing speed in flp-in and flp-in/tTS host cells.. ................ 81 
Figure 18. Sensitive CG sites to de novo DNA methylation by bisulfite 
pyrosequencing.. ............................................................................................................. 82 
Figure 19. Methylation patterns of pINSL6 in SW48A/tTS at the second month.. ....... 84 
Figure 20. The correlation of two assays in analyzing segmental methylation of 
pINSL6. .......................................................................................................................... 85 
Figure 21. Gradual accumulation of transgene methylation in SW48A/tTS over time, 
sampled at 2, 3, 4 and 5 months. ..................................................................................... 89 
Figure 22.  Methylation of two regions furthest away from pINSL6 which are inside of 
EGFP and hygromycin B. ............................................................................................... 90 
Figure 23. Comparison of transgene behaviors between the truncated and complete 
pINSL6 in SW48A/tTS.. ................................................................................................. 93 
Figure 24. Methylation profiles of pINSL6 in flp-in host cells by pyrosequencing. ...... 94 
Figure 25. Comparison of CGI methylation and GFP expression between tetO (-)-
pINSL6 in SW48A/tTS, tetO(+)-pINSL6 in SW48A and tetO(+)-pINSL6 in 
SW48A/tTS. .................................................................................................................... 95 
Figure 26. Regional methylation of transgenes in SW48A at the second month by 
pyrosequencing. .............................................................................................................. 96 
Figure 27. ChIP-qPCR for analyzing the enrichment of histone marks in pINSL6. ...... 99 
xiii 
 
Figure 28. The reaction of SW48A and SW48A/tTS clones to epigenetic drug treatment. .. 100 
Figure 29. Methylation profiles of pINSL6 of transgenes in flp-in host cells. ............. 101 
Chapter 4 
Figure 30. Methylation is not equally recovered in DKO cells.. .................................. 111 
Figure 31. Re-expression of DNMT3B1 in DKO cells moderately recovered global 
DNA methylation.. ........................................................................................................ 114 
Figure 32. Re-expression of DNMT1b in DKO cells moderately recovered global DNA 
methylation. .................................................................................................................. 116 
Figure 33. Preparation of DREAM libraries.. ............................................................... 122 
Figure 34. Overview of DREAM sequencing results. .................................................. 124 
Figure 35. Scatter plots for methylation distribution of SmaI/XmaI (CCCGGG) sites..
 ...................................................................................................................................... 127 
Figure 36. CGIs were not sensitive to re-expressed DNMT3B in DKO.. .................... 129 
Figure 37. Percentages of SmaI sites remethylated (top) and un-remethylated (bottom) 
in respect to their distance to the closest transcription start sites (TSS). ...................... 130 
Figure 38. Examples of remethylation and un-remethylation of CGIs in CGI-promoters.
 ...................................................................................................................................... 131 
Chapter 5 
Figure 39. A Model for late response of DNA methylation to transcriptional repression..
 ...................................................................................................................................... 139 
 
  
xiv 
 
List of tables 
Table 1. PCR primers and sequencing primers used for bisulfite-sequencing and 
pyrosequencing. .............................................................................................................. 33 
Table 2. RT-PCR primers ............................................................................................... 37 
Table 3. PCR primers for subcloning to constructs ........................................................ 38 
Table 4. PCR primers for confirmation of integration ................................................... 39 
Table 5. Inverse-PCR primers ........................................................................................ 41 
Table 6. Chip primer and probes .................................................................................... 42 
Table 7. Characterization of the single integration site in flp-in host cells. ................... 58 
Table 8. A list of genes with significant remethylation on at least one SmaI site of CGI-
promoters. ..................................................................................................................... 132 
 
 
1 
 
Chapter 1 
Introduction 
Cytosine methylation in normal mammalian cells 
DNA methylation, catalyzed by DNA methyltransferases (Dnmts), is a post-
replicative mechanism that regulates expression and conveys the epigenetic memory to 
progeny cells. This modification transforms cytosine to 5’methyl-C, which is restricted to 
CpG dinucleotides in mammalian gDNA (genomic DNA). Methylated CpGs are mainly 
distributed within repetitive elements (LINEs, SINEs, LTR, etc) and coding regions of 
functional genes, while unmethylated ones are often located in regions called CpG islands 
(CGIs). CpG islands are defined as the patches of DNA with at least 500bp length, CG 
content ≥55% and the ratio of observed CpG to expected CpG ≥65% (1). They are not 
methylated in germ cells, and most of them still keep methylation-free, especially those 
located at the promoters of housekeeping genes and tumor suppressor genes (TSGs). About 
half of genes have CGIs in their promoters, and methylation of them is often associated with 
gene silencing. Generally speaking, vertebrates use heritable DNA methylation to lock genes 
in silent states in order to act for self-defense against pathogens, maintain genomic stability, 
and regulate mono-allelic expression of imprinted genes, and so on. 
 
Basic functions of DNA methyltransferases 
The DNA methyltransferase (DNMT) family of proteins in mammals consists of 
several members with respective features in catalyzing the attachment of methyl-group to the 
5’-cytosine. DNMT1 is generally considered as the maintenance enzyme with higher affinity 
for the hemi-methylated DNA. It helps maintain established methylation patterns by working 
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with proliferating cell nuclear antigen (PCNA) at replication forks (2).  The dynamic binding 
of DNMT1 with PCNA accommodates the different kinetics of replication and DNA 
methylation, but is not absolutely required for methylation maintenance (3). The protein in 
charge of recognizing hemi-methylated DNA during replication is NP95 (also called uHRF1 
and IcBP90) in mammals, a SET-and RING-associated (SRA)-domain-containing protein. Its 
interaction with DNMT1 plays a dominant role in tethering DNA methyltransferase activity 
into replicating DNA (4, 5).  Of note, semi-conservative reproduction of methylation 
maintenance does not equal to precise copying at the level of a single CG dinucleotide, 
instead, it is the methylation status of DNA domains that appears to be faithfully propagated 
between cell passages demonstrated by heterogeneous methylation patterns in clonal 
population of cells (2).  
Different from DNMT1, DNMT3A and DNMT3B are dedicated to de novo 
methylation, which add methyl groups onto sites with absence of methylation at either strand. 
It is shown in Fig. 1 that most DNMT proteins share common C-termini that are responsible 
for the methyltransferase activity, while the N-terminal DNMT3A and DNMT3B consist of a 
cysteine-rich domain and a tryptophan-rich region (PWWP) domain and are required for 
directing enzymes to the major satellite repeats at pericentric heterochromatin (6). The N-
terminus of DNMT1 is composed of a different set of motifs for its interaction with other 
proteins and there is a linker region connecting the N- and C-termini that is absent in 
DNMT3’s structure. It is documented that sustained expression of DNMT3A and DNMT3B 
are required for the wave of de novo methylation during embryogenesis, and are still 
detectable in adult tissues though at lower levels than DNMT1 (7). DNMT3L is the 
homologue solely expressed in germ cells, and its structure keeps the PWWP domain and is 
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devoid of the functional catalytic domain and the cysteine-rich domain. Lacking the catalytic 
motifs, DNMT3L is considered as the cofactor for DNMT3A and DNMT3B in de novo 
methylation of dispersed transposons. 
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Figure 1. Structural overview of the functional domains of the DNA methyltransferase 
family. Most Dnmts share conserved motifs at the C-terminus. The N-terminus of Dnmt1 
includes a PCNA binding domain (PBD), a targeting sequence (TS), a cysteine-rich region 
(C), a polybromo homology domain (PBHD); while Dnmt3a, Dnmt3b and Dnmt3L consist of 
a tryptophan-rich region (PWWP) and another cysteine-rich region (C-rich) (Dnmt3L only 
has a C-rich domain). There is a region , (GlyLys)6 repeat between the N- and C-terminus of 
Dnmt1.Adapted from (7). 
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Further evidences are accumulating that DNMTs present functional co-operation or 
redundancy in both de novo and maintenance methylation. By in vitro methyltransferase 
assay with cell extracts and heterologous expression of DNMT1 in Drosophila cells, Dnmt1 
was observed to account for majority of de novo methyltransferase activity in cancer cells 
and methylate human CGIs integrated in the fly genome (8). Individually knockout 
DNMT3B in HCT116, a hypermethylated colorectal cancer cell, still retained about 87% 
methyltransferase activity and only led to less than 3% demethylation of global 5’methyl-C 
and modest demethylation of pericentric satellite (9). On the contrary, both double knockout 
(DNMT1-/-DNMT3B-/- HCT116) and severe genetic DNMT1 knockout (80%-90% reduction) 
in cancer cells resulted in >95% depletion of genomic 5’methyl-C, including DNA repeats, 
IGF2(insulin-like growth factor 2) imprinting and TSGs like p16INK4A (9, 10), which 
suggested the vital role of DNMT1 in somatic DNA methylation and cooperation from 
DNMT3B in maintenance of DNA methylation. Moreover, colocalization of multiple 
DNMTs at the promoters of hypermethylated genes (11-13), together with a high level of 
hemi-methylated LINE-1 and Alu elements in mouse ES cells lacking DNMT3A and 
DNMT3B, provide evidences for a new model where DNMT3A and DNMT3B are suggested 
to undertake the responsibility for maintaining methylation especially at repeats and 
imprinted regions as well as methylated CGIs through strong anchoring to nucleosomes (14-
16).  DNMT1, on the other hand, predominantly contribute to the bulk of DNA methylation 
during DNA replication (Fig. 2). 
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Figure 2. A proposed model for the maintenance of DNA methylation in mammalian 
cells. (a) During DNA replication, DNMT1 predominantly catalyze bulk-DNA methylation 
with the help of PCNA and/or UHRF1, and may contribute to error correction as well. (b) De 
novo enzymes, DNMT3A and DNMT3B retain bound to methylated CGs especially those 
occupied by nucleosomes. They are compartmentalized to CGIs and repetitive elements, 
perform ongoing de novo methylation which may not require recognition of parental strands 
and catalyze the leftovers of DNMT1. Blue nucleosome, newly assembled nucleosome; pink 
nucleosome, parental nuclesomes (14). 
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DNA methylation reprogramming during development 
Global DNA methylation patterns experience reprogramming during development. In 
mammals, the patterns inherited from parents are erased in fertilized eggs during pre-
implantation stage, and then restored to normal somatic level with a new embryonic pattern 
after implantation, which is established by combination of de novo and maintenance 
methylation. But reprogramming in paternal and maternal genomes in early embryos occurs 
through both active and passive mechanisms. Active demethylation in the paternal genome 
commences immediately after fertilization and before the first DNA duplication, while 
demethylation of the maternal genome is passively dependent on DNA replication due to 
exclusion of DNMT1 from the nucleus (Fig. 3). However, methylated imprinted genes and 
some repetitive elements do not become unmethylated such as paternal H19 gene, paternal 
LINE-1 and IAP, and maternal Alus. In the short window of postimplantation, de novo 
methylation re-establish methylation patterns to different extent in embryonic (EM) and 
extraembryonic (EX) lineages. Both the demethylated and unmethylated regions, including 
unmethylated maternal LINE-1 and IAP, paternal Alus, and microsatellite DNA in both 
parental gamete genomes, are engaged in this process except for some unmethylated 
imprinted genes (17-19).  
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Figure 3. Reprogramming of DNA methylation during early development in mammals. 
(A) Alterations of DNA methylation in gametogenesis. (B) Demethylation and re-
methylation in paternal and maternal genome during early embryogenesis (19). 
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The second stage is during gametogenesis when demethylation and de novo 
methylation also occur to set up parental-specific methylation in imprinted genes. 
Demethylation takes place in the early development of primordial germ cells (PGCs) (Fig. 3) 
when PGCs enter the gonads, lasts several days and is completed by the embryonic day (E) 
13 or 14 in both male and female germ cells. Remethylation in male germ cells occurs at the 
prospermatogonia stage (E15 to E16 and onwards), precedent to the time for female germ 
cells which is after birth during the maturation of oocytes (17-20). 
The essential role of DNA methylation in development is demonstrated from gene 
knockout or mutation in mouse ES cells or embryos. Disruption of DNMT3A, DNMT3B or 
both in mouse ES cells or embryos led to lethality although DNA methylation did not 
decrease much especially for single gene knockout (17). Genetic inactivation of DNMT1 also 
caused lethality but there is about 80% methyl-cytosine that lost methyl-groups without 
sequence specificity (21, 22). Similarly, the factors, like UHRF1, G9A, LSH, could induce 
extensive demethylation accompanied with lethality in ES cells and embryos. 
 
DNA methylation changes in cancer 
Epigenetic abnormalities have already been proved to collaborate with genetic 
changes in carcinogenesis. Concurrent with chromatin remodeling, altered DNA methylation 
including global hypomethylation and localized hypermethylation is correlated with genomic 
instability and aberrantly expressed genes. Loss of imprinting (LOI) due to demethylation 
concurrent with bi-allelic expression of IGF2 is correlated with a higher risk of colorectal 
cancers or Wilm’s tumors, a childhood renal cancer. Localized hypermethylation of promoter 
CGIs exists in various cancer types and is often associated with loss of TSG expression (RB, 
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p16INK4A, MLH1, MGMT, CDH1, etc). Also, methylated cytosines are susceptible to 
mutagenesis, like the case at TP53 coding region (23). Moreover, genomic screening of 
hypermethylated genes indicated a potential network of epigenetic events predisposing 
progenitor cells to transformation, as suggested in studies of SFRPs (secreted frizzled related 
genes) hypermethylation for permission of Wnt pathway in colon cancers (24).  
It is proposed further that multiple hypermethylated genes in certain colorectal 
carcinomas could be signatures of an epigenetic phenotype for cancer-specific markers – 
CIMP (CpG island methylator phenotype), correlating epigenetic defects with 
histopathological changes in cancer (25). Generally, CIMP is more likely to be at the 
proximal colon with more mucinous histology, more frequency of MSI (microsatellite 
instability) and more chance of BRAF mutations (26). The association of CIMP with genetic 
instability such as MSI or CIN (chromosome instability) is gradually revealed by genome-
wide research so as to predict the prognosis of certain colorectal cancers. For example, 
patients with BRAFV600E and MSI+CIMP+ phenotype, termed as CIMP-H, have better 
prognosis, in contrast to the worse outcomes for patients with BRAFV600E and MSI-CIMP+ 
phenotype (27, 28). More recent studies have suggested the existence of CIMP in multiple 
other cancer categories like glioma and ovarian cancer (29-31). In brief, altered DNA 
methylation is a possible early event in tumorigenesis and facilitates the colonization of 
precursor cells, therefore could be a kind of indicator for cancer subsets. 
What causes aberrant patterns of DNA methylation in cancer is awaiting clear 
illustration. It is still controversial as to the initiation directly by elevated DNMT levels. It is 
easy to relate the level of enzyme expression with abnormal methylation states since in the 
early embryonic development de novo DNMTs are downregulated once the pattern is 
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established. Artificial overexpression of DNMT1 in NIH3T3 or induction of DNMT1 by 
overexpression of FOS was able to promote cellular transformation (32, 33). As well, the 
moderate increase of DNMTs protein level or activity takes place in some cancers (24). 
However, it cannot explain the complex involvement of DNMTs in regional 
hypermethylation during development and neoplasia (8, 34, 35). 
 
Recognition of methylation signals 
The identified methyl-cytosine-binding proteins (MBPs) include three families of 
proteins with high affinity for methylated CpGs: the MBD domain family, Kaiso and Kaiso-
like proteins and the SRA domain proteins. The MBD family consists of the methyl-CpG-
binding protein 2 (MeCP2), the methyl-CpG-binding-domain proteins MBD1, MBD2, 
MBD3 and MBD4. They are involved in complexes containing histone deacetylase and 
histone methyltransferase activities as transcriptional co-repressors (36). All these proteins 
are expressed ubiquitously in somatic cells. Mice deficient for MBD1 and MBD2 are still 
viable with mild and indistinct phenotypes, while aberrant MeCP2 underlies most of Rett 
syndrome which is a neuro-developmental disorder with exclusive frequency in human 
females (37). There presumably are sequence-preferences for MBPs. The X-linked gene 
MeCP2 has higher binding in methylated CGs with adjacent enrichment for four or more A/T 
bases, which may depend on first MBD2 binding. Rather, MeCP2 seems dispensible for 
MBD2 due to occupancy of MBD2 in half of the binding sites under MeCP2 knockout (38). 
MBD1 also has higher affinity for some specific methylated CGs within TCGCA and 
TGCGCA sequence context than any other sequence which could be stabilized by its CXXC 
domain (39). From current studies, the recognition of certain subsets of methylated regions 
12 
 
for MBPs is attributable to their MBD domains and to some extent has overlapped target 
sites. 
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Figure 4. The model for the feedback loop of epigenetic regulations.   
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Epigenetic loop of transcriptional repression 
There could be two aspects of transcriptional silencing with the involvement of DNA 
methylation (Fig. 4). First, methylated DNA could preclude the localization of trancription 
activators to target promoters and both are exclusive to each other. Second, methylated DNA 
could induce sequential recruitment of multiple layers of proteins consisting of MBPs, 
histone deacetylases (HDACs), histone methyltransferases (HMTs) and related accessory 
factors, conferring compact chromatin structures to silence genes. As well, the other way 
around exists that histone modifications are prior to DNA methylation occurrence in some 
experimental systems. Thus, these factors form a loop of epigenetic regulation affecting gene 
expression. 
However, the dominance between histone changes and DNA methylation in gene 
repression is still controversial. One model describes DNA methylation as the original event, 
supported by the observations that in vitro methylated expression plasmids usually greatly 
decreases reporter gene expression (>90%) upon transient transfection into cultured 
mammalian cells (40) which is accompanied with deacetylated histones (41), and that loss of 
DNMT1 in human cells resulted in decreased H3K9me2 and H3K9me3 in pericentromeric 
heterochromatin(42). It seems that methylated promoters are not silenced until chromatin 
remodelling occurs (43). 
Another pathway suggests a primary role of repressive histone methylation in 
repression and DNA methylation as a secondary solidifying event. Increasing evidences 
come from diverse systems (23, 24, 44). Further studies indicated the cooperation between 
DNA methylation and H3K9me can be dissected by recognizing the specific target residues 
of HMTs. They observed siRNA knockdown of DNMT1 impaired DNA methylation, G9a 
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loading at replication loci and H3K9me, but Suv39h1 activity still remained (45). The same 
controversy exists for H3K27me3. This mark, like H3K9me3, can be concurrent with gene 
silencing but without DNA methylation. It is demonstrated that Ezh2 is associated with three 
major DNMTs via its N-terminal portion (46), and the PcG-target genes would be susceptible 
to de novo methylation in cancer as they are pre-marked by H3K27me3 during early 
development (47, 48). However, data from Ezh2-depleted U2OS and RKO showed DNA 
methylation and silencing still persisted at target promoters (p16, hMLH1, MYT1 and 
WNT1) (49). Another possibility is that polycomb-mediated H3K27me3 and DNA 
hypermethylation may not have the expected direct contact and can act in parallel depending 
on certain cell status, as suggested in several recent papers (50, 51). There seems more results 
supporting the precedency of transcriptional repression and chromatin remodelling over 
DNA methylation. 
 
DNA methylation spreading and protection 
 Heterochromatin is the condensed domains interspersed by the decondensed euchromatin. 
It is characterized by enrichment for methylation of H3K9 and/or H3K27, lack of acetylation 
of histone, occupant with HP1 and also, high levels of methylated CGs. Without the 
protection of boundary elements, heterochromatin state is prone to extend to adjacent areas, 
which is realized by the feedback loop of DNA methylation, histone modification and 
chromatin remodeling with the help of adaptors like HP1. As shown in some genes like 
estrogen receptor (ESR1), it is likely aging participates in initiation of this spreading process, 
so the aging-dependent promoter methylation could be associated with the risk of some 
cancers, although this has not been clearly clarified (52, 53). The mechanisms of 
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heterochromatin spreading are not defined yet, and models proposed to explain long-range 
spreading of silent chromatins all involve dynamic reorganization of higher chromatin 
structures. For instance, in the “oozing” model, sequential assembly of sets of proteins is 
facilitated by one particular protein binding; the “looping” model talks about long-distance 
fiber-fiber connections mediated by certain organizers; not to mention the factors in the 
“sliding” model are tracking down a chromosome with transcriptional complexes; and so on 
(54). 
 Normally, spreading can be resisted by protection from insulators (54-56). According to 
specific local features, some insulators work as enhancer-blocker, others as barriers. The 
enhancer blocking insulators are defined as sequences being placed between the enhancer 
and promoter while interrupting their interaction. A classical example comes from the studies 
of imprinted Igf2-H19 locus where there are a run of CTCF-binding sites in the ICR situated 
between the enhancer and the Igf2 promoter. Paternal genome expresses Igf2 because 
paternal-specific methylation of ICR abolishes the blocking via CTCF binding (57, 58). It is 
possible that CTCFs position the enhancer and promoter into separate domains by interacting 
and clustering as well as tethering the chromatin fiber to the nucleolar surface thereby 
forming loops and preventing inter-loop contacts; alternatively, some activation signals travel 
from the enhancer to the promoter which is stopped by half-way CTCF deposition (59). The 
barriers are the reason for PEV (position effect variegation) which is spreading of heritable 
silencing to euchromatin from heterochromatin. The cHS4 locus lying at the 5’-end of the 
chicken β-globin locus has complex functions of both enhancer-blocker and barrier. CTCF 
mediates the strong enhancer-blocking activity, and transcription factors USF1 and USF2 
cooperate as barriers due to recruitment of HAT and HMT to catalyze histone deacetylation 
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and H3K4 methylation together with chromatin remodeling complex, thus “openness” stop 
the spreading of heterochromatin  (60). Other transcription factors like Sp1/Sp3 could also 
protect histone-based silencing against spreading and lead to variable DNA methylation. For 
example, the RIL (PDLIM4) gene promoter is present in two forms of alleles: the long allele 
has additional 12-bp insert (CGGCGGCGGCTC) and a substitution of T to G 3 bases 
upstream of the insertion site in the short allele, which is later found as a Sp1/Sp3 binding-
site so as to create a local protection in the long allele which usually has less methylated CG 
frequency (61). 
 
Methylation center definition 
 How heterochromatin is nucleated at specific chromosomal domains remains elusive, 
though evidences suggested certain cis-acting sequences like silencers and repetitive 
elements could provide signals for nucleation (62). Because the phenomenon of DNA 
methylation spreading has been observed in aging and cancerous cells from CpG island 
borders into transcription start sites (TSSs), the “seed and spread” model of DNA 
methylation is proposed to explain the distinct methylation patterns and related silencing 
events in pre- and post-neoplasm (63, 64) (Figure 5). The methylation center is hypothesized 
as the region initiating DNA methylation and recruiting de novo DNMTs. Turker M.S. and 
colleagues identified two upstream B1 repetitive elements as cis-signals for de novo 
methylation of mouse Aprt gene on the X-chromosome, and methylation spreading is resisted 
by undetermined factors binding to one of the Sp1 sites between retrotransposons and its 
CGI-promoter (65-68). Other retrotransponsons were also suspected methylation centers, 
such as human Alu, mouse LINE-1, B2 and IAP (16, 69-72). A series of genes (p16INK4A, 
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ER, hMLH1, VHL, CDH1, etc) are silenced concomitant with hyper-methylated CGI-
promoters in colorectal, breast, prostate and hematopoietic cancers. The common feature of 
these genes is a CGI-promoter surrounded by consistently methylated upstream or/and 
downstream repetitive elements in both normal and malignant conditions. Therefore, these 
genes with such methylation patterns are considered as possible candidates to study 
methylation centers.  
 The concept of “methylation centers” brings up consideration of the original trigger for 
DNA methylation. Does DNA methylation directly deal with specific sequences, or 
indirectly result from other processes which possess site-preferences? Both cases may coexist 
during physiological and abnormal development. 
 It is easy to first examine the sequence preferences of DNMTs, particularly de novo 
DNMTs (DNMT3A, DNMT3B, and even DNMT3L in germ cells). The machinery of 
attracting de novo DNMTs could depend on the discrepant substrate preferences of the 
enzymes. For instance, both Dnmt3a and Dnmt3b favored RCGY with AT-rich flanks and 
disliked YCGR (34, 73). While this may be true, it cannot explain the complex involvement 
of DNMTs in regional de novo methylation during development and neoplasia (8, 34, 35). A 
hypothetical  target is DNA repeats which account for the high level of global DNA 
methylation and about 25% of promoters are surrounded by repetitive elements (74). The 
suggestive evidence in mammals is that high copy number of transgene induced significant 
repression along with DNA methylation (75).  
 Many recent studies reveal components participant in chromatin and nucleosome 
organization are very likely more decisive than just DNMTs, and they involve all the aspects 
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of epigenetic regulators including histone modification, chromatin remodeling factors, micro-
RNA and even nuclear skeletal molecules. 
 
Components in controlling DNA methylation — transcriptionally repressive histone 
signatures and their modifiers 
In epigenetic regulations, the combined status at the N-termini of histones has 
become the indicator for chromatin organization and transcriptional activity. Generally, H3 
acetylation and methylation of histone3 at K4, K36, and K79 are linked to gene activation, 
whereas H3K9me3, H3K27me3 and H4K20me3 are hallmarks for repressive status (24). 
Each histone methylation has its own catalysis system and distribution patterns. H3K9 
methylation is catalyzed by several types of histone methyltransferases (HMTs). Suv39h1 
and Suv39h2 are responsible for tri-methylated H3K9 which is more associated with compact 
and transcriptionally inactive heterochromatin at pericentromeric areas and recently mapped 
to silenced euchromatic genes; mono- and di-methylation, catalyzed by G9a/GLP 
(EuHMTase), seem to be restricted in euchromatic regions, although H3K9me1 is mainly 
found around TSSs of actively transcribed genes (24, 44). Another crucial repressive histone 
mark H3K27me3, is catalyzed by Ezh, one of the PRC2 (polycomb repressive complex 2) 
components, assisted by two PcG (polycomb group) proteins of Eed and Suz12 and a 
member of the Jumonji C (JmjC) domain protein family, Jarid2 (76, 77). The H3K27me3 is 
further maintained by PRC1, also composed of several PcG proteins, leading to occlusion of 
transcription machinery and compaction of chromatin. The PcGs are not only involved in 
maintaining cell identity during development, but also in tumorigenesis, as shown by 
increased expression of Ezh2, Eed, Suz12 and Bmi in colon and breast cancers. The 
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enrichment for H3K27me3 is primarily found in imprinted genes, inactive X-chromosome 
and almost all the DNA hypermethylated and silenced cancer genes (44, 78).   
As mentioned in the previous part, the enzymes for histone modification do interact 
with DNMTs. Experimentally, this interaction does not rely on the enzymatic domains, 
namely SET domain, to assemble DNMTs into the complex. One example is mutation of the 
SET domain in G9a could not affect related DNA methylation at the time of eliminating 
H3K9 methylation, that is, DNMT3A and DNMT3B are still located through biochemical 
interaction with another domain and histone methylation is not responsible for their binding 
(79, 80). This dispensability of histone modifications for DNA methylation also holds true 
for other SET-domain-containing enzymes, such as SETDB1, SUV39H1 and EZH2 (46, 81, 
82). Accordingly, although DNA methylation could be set up at the early stage of 
development or carcinogenesis, it possibly would be a late-response step in gene silencing to 
consolidate local memory of repression and facilitate its heritability. This has been shown in 
series of micro-array analyses in cancers that many methylation events were observed in 
promoters where expression is already shut down in normal cells (83). The occurrence of 
silencing events and histone modifications prior to DNA methylation is also demonstrated in 
repression of specific promoters like p16INK4A silencing in primary human mammary 
epithelial cell (HMEC) strains during selection which is a model for early breast cancer (84). 
Therefore, there may be three steps in setting up epigenetic marks on silenced genes. First, 
transcription factors are induced to bind specific promoters and transcription is turned off, 
and this is a reversible silencing stage. Second, the previous active marks are removed and 
enzymes are recruited to add repressive modifications to residues, such as G9a for H3K9me, 
to create local heterochromatin, which is still a flexible stage. Finally, DNA become 
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methylated aided by enzyme (e.g. G9a)-containing complexes and a stable inactivation is 
stamped on the local regions which can be inherited over cell proliferation (85). 
 
Components in controlling DNA methylation — chromatin remodeling factors and 
nucleosomes 
The appropriate DNA methylation is ensured through association of accessory factors 
with DNMTs. The SWI/SNF chromatin remodeling complex regulates the accessibility of 
DNA to transcription machinery by mobilizing the octamers. Both ATRX and Lsh, members 
of the SNF2 helicase family, have been indicated to have effects on global methylation 
patterns (86, 87). Lsh, as a sequence-specific regulator, has direct associations with DNMT3a 
and DNMT3b instead of DNMT1, suggesting its connective roles in de novo methylation 
(88-90).  
Heterochromain protein 1 (HP1α, HP1β, and HP1γ in mammals) is an adaptor 
involved in multiple facets of chromatin configuration. Its functions are related to 
heterochromatin formation and gene silencing, telomere capping and silencing, and positive 
control of gene expression (91). The plasticity of HP1 in chromatin organization is 
determined by its variant isoforms and binding partners, including the direct association with 
DNMT1 in repression of euchromatic genes and colocalized with DNMT3A and DNMT3B 
in heterochromatin as well (92, 93). 
 
Components in controlling DNA methylation — small RNAs and long non-coding 
RNAs 
22 
 
MicroRNAs are a class of 19-25nt, single-stranded non-coding RNAs originated from 
genomic loci. It is clear that plants, worms and fission yeasts all have transcriptional gene 
silencing (TGS) as well as post-transcriptional silencing (PTGS) mechanisms in their gene 
regulation. However, the details of TGS in mammals still remain unclear. Most of the 
evidences for RNA-dependent DNA methylation (RdDM) come from exogenous RNA 
strands. Morris et al. observed gene inhibition with DNA methylation, H3K9me3 and 
H3K27me3 was induced by promoter-directed siRNAs in human cells (94, 95). Studies have 
shown the link between de novo DNA methylation and piRNAs (piwi-interacting RNAs) in 
germ cell development (96, 97). On the other hand, short dsRNA (double-strand RNA) 
targeted at the CpG island of CDH1 promoter induced TGS in cancer cells without CpG 
island methylated (98). Taken together, miRNAs may contribute partly to selective promoter 
hypermethylation in cancer cells (99), and the differences in experimental designs targeting 
at coding or promoter regions may be responsible for the controversial results.  
The role of long non-coding RNA (lncRNA) in targeted de novo methylation is 
another interesting aspect and still needs further proofs. It has been suggested from studies of 
X chromosome inactivation and gene imprinting. In the mouse embryos, non-coding 
chromosome RNA expressed from Xist gene on the inactive X chromosome triggers the 
inactivation prior to the CGI-promoter silencing through PRC2 (100).  
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Figure 5. The model of "methylation center" and protection around the CpG-promoter. 
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Genome-wide methylation profiling approaches (next-generation sequencing) 
The first generation of sequencing mainly refers to the automated Sanger sequencing, 
and more recent developed methods are considered as the next-generation, which have 
become commercially available platforms from Illumina/Solexa, ABI/SOLiD, Roche/454, 
and so on. These sequencing methodologies require multiple steps including library 
preparation, amplification, sequencing, imaging and data analysis, which generate millions of 
reads per run. Compared with micro-array technologies, they have the advantage of covering 
repetitive elements and assigning the features to specific alleles.  
Coupled with these newer sequencing technologies, approaches to obtain genome-
wide profiles of DNA methylation have come out. Basically, some require bisulfite-
converted genomic DNA for template preparation like MethylC-seq and RRBS (reduced 
representation bisulfite sequencing) (101, 102), some are based on enrichment of methylated 
DNA like MeDIP-seq (methylated DNA immunoprecipitation sequencing) and MBD-seq 
(methylated DNA binding domain sequencing) (103, 104), and some utilize the methylation 
sensitive characteristics of restriction enzymes to digest genomic DNA. Each method has its 
own advantages and disadvantages with respect to covered regions, sequencing depth, 
accuracy, cost and so on. For example, MeDIP-seq and MBD-seq are not able to go deep to 
single base resolution but can reflect high to medium methylation of stretches of DNA and 
covers broader regions; the bisulfite-based methods, in contrast, allow quantitative 
comparison down to single nucleotides but are limited to CGIs and promoters (105, 106). 
DREAM (Digital restriction enzyme analysis of methylation) is an enzyme-
recognition-based approach which quantitatively maps DNA methylation with high 
resolutions. This technique employs restriction enzymes, such as SmaI and XmaI, to generate 
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“unmethylated” and “methylated” overhangs for digested DNA fragments, which can be 
modified to enter the subsequent pipeline of one next-generation sequencing platform (e.g. 
HiSeq2000 or GA II from Illumina, SOLiD from Applied Biosystem) (Fig 6). The 
discrimination of “unmethylated” and “methylated” CG dinucleotide results from the ability 
of a pair of restriction enzymes to be blocked by methylated cytosines. For example, when 
using sequential digestions by SmaI and XmaI, the first reaction products are fragments with 
blunt ends (5’-GGG and 3’-CCC) to reflect “unmethylated” CG since SmaI is blocked by 
methylated CG; the following digestion by XmaI leaves sticky 5’-overhangs (5’-CCGGG 
and 3’-C) representing “methylated” CG although XmaI has no such preference. After end 
repairs and adaptor ligation, specific sizes of ligation products are selected and amplified 
with high-fidelity, which then are ready for large-scale sequencing. Because there is no 
bisulfite-treatment so that the methylation ratio for a specific CG site can be calculated, the 
methodology of DREAM has no bias for either state and the error rate is less than 10% 
(unpublished data). With the decreasing cost and improved depth of sequencing, DREAM 
can also be very cost-effective to study epigenomes of various diseases and cancer.  
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Figure 6. Profiling DNA methylation by DREAM analysis.  
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Hypothesis and Specific Aims 
 
I. CGIs are usually places precluded from DNA methylation, and only a small fraction of 
CGIs, particularly promoter-CGIs, is densely methylated in somatic cells (74, 107, 108). 
Aberrant promoter-CGI methylation has also correlation with abnormal gene expression 
in cancers. Repetitive elements account for almost half of genome sequences, and about 
25% of promoters are surrounded by repetitive elements (74). Consistent high levels of 
cytosine methylation often feature upstream and downstream of CGI-promoters which 
become hypermethylated in malignant states, such as p16INK4A, ER, hMLH1, VHL, 
CDH1, etc. Intriguingly, many of the promoters contain adjacent repetitive elements (e.g. 
LINEs and SINEs). RIL (PDLIM4) and INSL6 identified by us also share the same 
features as the above genes (108, 109). Accordingly, we hypothesize that CGI-promoters 
contain cis-elements responsible for de novo DNA methylation. 
Aim 1. Identify CG sites in sample CGI-promoters with priority for DNA 
methylation. 
Aim 2. Assess the roles of repetitive elements in methylation spreading. 
Aim 3. Assess the involvement of different local environment in DNA methylation. 
We establish a site-specific integration system to ensure every constructed transgenes 
inserted into the same genomic locus. This study system is generated in two colorectal cancer 
cells and has two magnitudes of strength of repression. By stable transfection, constructs 
with variable fragments from sample CGI-promoters will experience de novo DNA 
methylation, if it could occur, so we expect differential sensitivity of CG sites to DNA 
methylation under the inner pressure of cell lines and integration loci. 
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II. Hypermethylated CGI-promoters in cancer cells suggests de novo DNA methylation still 
functions in somatic cells, no matter it is a bona fide process or superimposed on scarcely 
distributed methylation background, since DNMT3A and DNMT3B are still detectable 
though significantly less than during early embryogenesis. DNMT1-/- DNMT3B-/- 
HCT116 (DKO) is a relatively well-characterized cell line generated from HCT116 
which is a colorectal cancer cell with high methylation environment. The DNA 
methyltransferase activity has been almost abolished in these double-knockout colorectal 
cancer cells by serial homologous recombinations (9). Even though there is still 
DNMT3A present and the possible alternative transcript of DNMT1, both of which 
account for the remnant DNA methyltransferase activity in DKO, about 95% of genomic 
methylation is lost and DNMT1 contributes more (~20%) to the reduction than DNMT3B 
(~3%) (8, 9). Simply, the DKO cells do not keep the methylation patterns in HCT116. 
Therefore, we propose the hypothesis that the loading sites of DNMTs are involved in de 
novo methylation at CGI-promoters and adjacent regions. 
Aim 1. To identify the genes whose CGI-promoters are sensitive to re-expressed 
DNMT3B in HCT116 DKO cells (DNMT1-/- DNMT3b-/-). 
Aim 2. To dissect the common features of remethylated sites caused by re-expressed 
DNMT3B. 
A high-throughput sequencing method is performed to identify sets of sites or regions 
with distinct sensitivity for remethylation caused by re-expression of DNMT3B or DNMT1 
in HCT DKO cells. We expect to observe methylation changes in CGIs vs. non-CGIs, or/and 
in promoters vs. non-promoters, which have undergone significant demethylation in DKO 
29 
 
cells. The new occurrence of methylated CG sites could, in some sense, reflect the pre-
existent epigenetic signatures of the host cells. 
  
.  
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Chapter 2 
Methods and Materials 
 
Human samples 
Patient samples of colon cancer tissues and normal colon mucosa were collected from the 
Johns Hopkins Hospital. Samples of normal blood were obtained from the University of 
Texas MD Anderson Cancer Center. All specimens were given informed consent by patients 
prior to collection of specimens according to institutional guidelines.  
 
Cell culture 
The colorectal cancer cell lines, SW48 and HCT116, obtained from the American Type 
Tissue Culture Collection (ATCC), were maintained in Leibovitz's L-15 Medium and 
McCoy's 5a medium modified with 10% fetal bovine serum. HCT116 DKO (DNMT1-/- 
DNMT3b-/-) was generously gifted from Dr.Stephen Baylin at the Johns Hopkins University, 
and passages were cultured in McCoy's 5a medium modified supplemented with 0.4 mg/mL 
G418 and 0.05 mg/mL hygromycin B.  
 
DNA extraction and bisulfite conversion 
Genomic DNA was extracted from cell lines or tissues using standard methods.  Every 
106 cell pellet was lysed by 600 µl cell lysis solution (25mM Tris-Cl pH 8.0, 10mM EDTA 
pH 8.0, 1% SDS) with 1.5 μl RNase A Solution, mixed well and incubated for 30 min at 37 
ºC. 200 µl of 7.5M Ammonium Acetate was then added and vortexed. After centrifugation, 
the supernant was transferred to a new tube for phenol-chloroform extraction, and the upper 
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aqueous phase was further precipitated with isopropanol. The final pellet was dissolved in 50 
µl 10 mM Tris-Cl (pH 8.5) after 70% ethanol washing. DNA concentration was measured by 
NanoDrop™ 1000 spectrophotometer (Thermo Scientific).   
Bisulfite conversion was performed with EpiTect Bisulfite Kits (Qiagen). According to 
the instruction, less than 2 µg of genomic DNA was input to every conversion reaction, and 
the final purified converted DNA was eluted with 20 µl 10 mM Tris-Cl (pH 8.5). 
 
PCR, cloning and DNA sequencing (Bisulfite cloning/sequencing) 
PCR SuperMix High Fidelity (Invitrogen) was used to amplify from gDNA and 
amplicons were subsequently ligated to PCR4-TOPO (Invitrogen), transformed into 25 µl 
One Shot TOP10 chemically competent E.coli (Invitrogen) and colonially selected on LB 
plates with 100 mg/ml ampicillin. Each correct TA-clone was confirmed by PCR with M13 
forward (-21) primer (GTAAAACGACGGCCAG) and M13 reverse primer 
(TCACACAGGAAACAG CTATGAC), and the amplicon was used for Sanger sequencing. 
Primers for amplification of the bisulfite-converted DNA are listed in Table 1. 
 
Bisulfite pyrosequencing 
All templates used for pyrosequencing were PCR products amplified either using PCR 
SuperMix High Fidelity (Invitrogen) or Taq DNA Polymerase (NEB), which were produced 
through nested PCR or one-step PCR reactions with one biotin-labeled universal primer 
(GGGACACCGCTGATCGTTTA) and one normal primer. Please refer to Table 1. for 
primer informations.  
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Generally, 1 to 2 µl of bisulfite-converted DNA was used for PCR reactions and the 
biotinylated products were subject to sequential steps to immobilize the biotinylated single-
strand onto streptavidin-coated beads, including mixing PCR products with beads, agitation, 
capturing beads, denaturing, washing and annealing sequencing primers. The sequencing 
process then was automated on the PSQ™HS 96 (Qiagen) equipment, and results were 
analyzed and output through Pyro Q-CpG Software (Qiagen) software.  
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Table 1. PCR primers and sequencing primers used for bisulfite-sequencing and pyrosequencing. 
Name Step Forward Reverse Sequencing Target Sequence Ta (°C) Size (bp) 
BSP 1° GGTAYGATGGAAAGTAAGAATAG TCCAACTCRACCAAAATAAACAC NA NA 50-58(53) 642 
INSGFP-P1 
1° GGTAYGATGGAAAGTAAGAATAG  TCCAACTCRACCAAAATAAACAC   53 642 
2° GTAAGATGGAAAGTAAGAATAGA U-AAAAACCCCCTATCATCTCT 
TAAGTTTATAAATGGAAA
TA GGTYGATTAATATYGTGAAA 50-61(58) 128 AGGTTTTTGTTTTTATGAA
G  
YGGGGGTTTTAGGAAAGAGGTTAT
AYGTTTAT 
INSGFP-P2 
1° GGTAYGATGGAAAGTAAGAATAG  TCCAACTCRACCAAAATAAACAC   53 642 
2° 
U-
TAGGAGTAGATAGGGAGTAG
G 
CTCCACCAAAATAAACAC AACCCCAAACTAATCCT  CCRCRTTATACAATAAC 50-61(58) 200 
INSGFP-P3 
1° GGTAYGATGGAAAGTAAGAATAG  TCCAACTCRACCAAAATAAACAC   53 642 
2° 
U-
TGAGGGAGAAGAAGTTTTAT
TAA 
 
CCCCCTAATTTAATTCATTT 
TCCCTCCACCTAAAATAC RTTTCTCRTTCTTATTTA 
54 174 AATAAAAAATTCCTCACC
A AACRTAAAAACA 
INSGFP-P4 
1° GGTAYGATGGAAAGTAAGAATAG  TCCAACTCRACCAAAATAAACAC   53 642 
2° 
U-
TTTTGGTTTTTATTTTAGGAG
TTAG 
CCCCTTACTCACCATAATAAC CCAACCCTACTCCCTATC TACRCCTACRCCAAACCRAACRACRCRCAC 50-62(58) 329 
tetOINS-P1 
1° TTYGGGATTTGGTATTTAGTTG CCGGAAACTCATACCCTAAACTC   50-58(55) 707 
2° AGGGATTTGGTATTTAGTTGGTAATT 
U-
ACCCATACCTCCCTATAAACCAA
TAA 
TGGTAATTAAATATGTGGT
G 
AAAYGTTTAAGTGTTGTATATGGT
TATGTGYGTTTAGTTA 50-62(58) 129 
tetOINS-P2 
1° TTYGGGATTTGGTATTTAGTTG CCGGAAACTCATACCCTAAACTC   50-58(55) 707 
2° TTGAGGTATTTGGGATGGAAATT 
U-
CAAATCCTCTAAAAATCCCTATC
ACA 
GGATGGAAATTTGGTTTT TTYGGTTAGATAA 50-62(58) 99 
tetOINS-P3 
1° TTYGGGATTTGGTATTTAGTTG CCGGAAACTCATACCCTAAACTC   50-58(55) 707 
2° GATAATTTTGTTTAGTTAGGA U-AAACTCATACCCTAAACTC TTTATTATTGATAGGGAGTAAAT TYGATATAYGTTTTTTATTA 50-58(58) 390 
RILWH-P1 1° ATGAAGAATTTGTTTAGGGTTAGG 
U-
AAACATTCAAACCTTCTCTTACT
ACTTA 
AGATGTAAGGGTTAGATA
TA YGYGTTGATATTGATTATTG 50-58.9 198 
RILWH-P2 1° GTTTAGTGTGGTGGAATTTTGTAG AACCRCRAACCCAAACCCAAC   58-62(58) 487 
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2° GGTGGTTTGAGAGGAGTTTGTAA 
U-
TATCCACACCCACCCTTTAAAAT
C 
TTTTTTATAAGGTAGGATG
G 
GTYGTAGGTGTGTTAGTYGGGTTT
AT 50-62(60) 401 
RILUP-P2 
1° TAGTGTGGTGGAATTTTGTAGA CACTATACTAAAAACTACCCCAA   52-62(55) 394 
2° AGAAGGTTTGAATGTTTTGGGGAAGTA 
U-
TACCCCAACTCAAATACCTCCTC
ATAA 
TTTTTTATAAGGTAGGATG
G YGYGTTGATATTGATTATTG 50-62(58) 286 
RILCEN-P 
1° GTTTAGTGTGGTGGAATTTTGTAG ACCCTCCCACTTCRAAAAACTCT   50-62(55) 319 
2° AGGTGTAGATAGTTGGGTTTGGG U-CACACCCCCACTCAACTCTC 
AAGGTTAGAGTAGGATTT
AG 
GTYGTYGGGGTYGTTYGAAYGYG
GGGATTT  50-62(55) 113 
RILDN-P1 1° ATGAAGAATTTGTTTAGGGTTAGG 
U-
ATCCACAATAACTCCCCCAAATA 
AGATGTAAGGGTTAGATA
TA YGYGTTGATATTGATTATTG 58 333 
RILDN-P2 
1° TAGTGTGGTGGAATTTTGTAGA CRAAAACCCCAAACCTCCCTAAA   58 421 
2° 
U-
TTTGGGGGAGTTATTGTGGA
T 
CAAAACCCCAAACCTCCCTAAAT CCCCTAACCCATCTC CRCRAATCCTTCCCRAATCCAC 60 196 
P16UPF-P1 1° ATGAAGAATTTGTTTAGGGTTAGG U-TAAACACCCTCCACTAATCA 
AGATGTAAGGGTTAGATA
TA YGYGTTGATATTGATTATTG 58 96 
P16UPF-P2 
1° TGAAGAATTTGTTTAGGGTTAGG ATCTCTCCACCACCCTCC   50 548 
2° TTTTAGGTTGGAGTGTAATG U-CTCTATAATCCCAACATTCT GTAGTTGGGATTATAGGTAT GYGTTATTAAGTTTYGTTAATTTTG 50-55 243 
P16UPF-P3 
1° TGAAGAATTTGTTTAGGGTTAGG ATCTCTCCACCACCCTCC   50 548 
2° YGTTATGTTGGTTAGGTTT U-ATCTCTCCACCACCCTCCA TTAGAATGTTGGGATTATAG 
AYGTGAGTTATYGTATTYGGATTT
T 52-58 207 
P16UPR-P1 1° ATGAAGAATTTGTTTAGGGTTAGG 
U-
ATTCCCTTCCCCCTTTATAATTAC 
AGATGTAAGGGTTAGATA
TA YGYGTTGATATTGATTATTG 58 166 
P16UPR-P2 
1° TGAAGAATTTGTTTAGGGTTAGG CACACRTACRCCACCATAACCAA   50 501 
2° GGGGTTGTTGTGAGTTTAAATGAT 
U-
TACCCCACCATAACCAACTAATT 
AATTTTAGTATTTTGGGAA
G TYGAGGYGGGTAGATTATTTGAGG 50-55 306 
P16DNF-
P1 1° 
ATGAAGAATTTGTTTAGGGT
TAGG 
U-
ACCACAAATTTCCACTAATAATC
C 
AGATGTAAGGGTTAGATA
TA YGYGTTGATATTGATTATTG 58 114 
P16DNF-
P2 
1° TGAAGAATTTGTTTAGGGTTAGG CTAAAACATAAACTCCAACCAC   58 601 
2° GGAGGGATTATTAGTGGAAATTTG 
U-
TTCTTTCCACAAAATCTCACTCTA AGGTTGAGGTAGGAGAAT YGTTTGAATTYGGGAGGTTG 60 370 
P16DNR-
P1 1° 
ATGAAGAATTTGTTTAGGGT
TAGG 
U-
CCCTTATAATCCCTTCACTTTAAA 
AGATGTAAGGGTTAGATA
TA YGYGTTGATATTGATTATTG 58 466 
P16DNR-
P2 
1° AATTTYGGTTYGAGTTTAGGGTAT 
TCAAACRATTCTCCTACCTCAAC
C   58 335 
2° GTGTTGGATATTAGGAGGGA U- TGATAGAAATTATTTAGA YGGTYGGGYGYGGTGTTTTAYGTT 58-62 241 
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TTAT CCACCCCCCACTACTTTTTATAT AG TTGTAA  
EGFP-P 1° AAGGAAGAAGGTAATTATAAGA U-CCAACTTATACCCCAAAAT 
GGAAGAAGGTAATTATAA
GA 
TTYGYGTYGAGGTGAAGTTYGAGG
GYGATAT 50-52 124 
HYG-P 1° AGGGTGTTAAGTTGTAAGATT U-TCCCCCATATAAAATCAC 
AATTGTTAGTTGTTTTGTA
G 
TYGGTYGYGGAGGTTATGGATGYG
ATYGTTGYGGTYGATTTT 50-52 174 
siteD-P1 1° GTAAGAGTAGAAATAGGGGAAGA U-CATCTCCCTTAACTTCACAA 
AATTAGTTTTTTTTTTATG
A 
YGGAGTAAGGATGGAGAATAAGG
ATATYGGTTTA 50-58 277 
siteD-P2 1° AGAGATGTAGTAGGTAGTTGGATATA 
U-
AATTAAAACCAATACTTACATAT
TC 
TTTTATAGTATAAGTTTAT
AGGG 
TAYGAAGAATGAATTTTGAGAATG
TTTGG 50-58 75 
siteA-P1 1° AGTGTATTTGGGGATAAGA U-TCTTTCACCACTTAATTAATC TTATGATAGATATTTGGTAA AYGATGGAAATGT 50-52 78 
siteA-P2 1° AGTTTAGGTTTTTGGAATGTAG U-TTATTTACTCACCTTCTTTACAT 
TGTATTTAGGTTAATTTAT
G TTGTATTTGAATTYGAYGTTAA 50-52 243 
Zeo-P1 1° AAGTAGTGATTGGGAAAAT U-CATTCCCCATTCAAACTA ATTGGGAAAATTTTGG YGTTATTTAATTTAATYGTT 50 138 
Zeo-P2 1° GGTTGATTAATTTTTTTTATT
TATGT 
U-
AAACTTCCAAATAATAACTTCTC 
TTTTTTTTATTTATGTAGA
G 
GTYGAGGTYGTTTYGGTTT 50-52 120 
 
Name Forward Reverse Sequencing Target sequence Ta (°C) 
Prod. 
Size 
(bp) 
RIL-8 GGGAGGGGGTTGTGTAGATA CCCCCACTCAACTCTCAAAA na na 52 523 
RILEF GATATATAGGGGATTTGGGTTT U-TCCTCAAAATCCRACTCAAACT AGTTTTAGGGAGAAGGTT yGyGTAGGGTTAyGGAATGGG 52 227 
   GAGAGAATTAGGTTTTAGATATG 
GGATyGTTTTGTyGTTAyGTAGTy
GTTAG 52 227 
RIL-10 TTTAAAGTGGGAAGTGGATGGATT AAACGCCCAAACCAACCCTCC na na 52 353 
RIL-D GTTTATTAGGYGGAAGTTTTAGG U-AACCAATCCAAACRCACAA GGTTAAGGAATGGGGTA TYGYGGGTTGGAGTYGTAGTYGGAG 54 221 
RIL-G GAGTTTTTGGGTTTTTGTAGAG U-TCCCACCTAAACCTATCTACC GGTTTTTTTAGATGAGGTTA GyGGGGAGGyGGGTGyGTGAA 55 160 
SFRP1 1° GGGGAATTTGTTATATTTAAGTATTT ATACCCCTACTCAACAAAAACTACC   56 192 
SFRP1 2° GGGGAATTTGTTATATTTAAGT ACACCCAAATCTTCCTCTA AGTAGAAGTAGAAGAATTGT ATGATYGGTTYGTAYGAGT 58 161 
SFRP2 1° GGTTAGGTTTTTTTGTTTGTTGTTTAA U-CTCACCCCCTTACTAAAAAAAAATTC   57 104 
SFRP2 2° AGGTTTTTTTGTTTGTTGTTTAAAGA U-CTCACCCCCTTACTAAAAAAAAATTC 
TGTTTGTTGTTTAAAGAAAT
T TTAGGGYGGGYGAGYGGYGG 59 100 
SFRP4 1° GTTGTGGTTGTATATTTTTATGAG CCATTTACACCCTAAAATTC   55 107 
SFRP4 2°  U-TTACACCCTAAAATTCCTACAC TGTGGTTGTATATTTTTATGAG 
GGGTTYGTAGTYGTYGYGYGYG
YGTT 58 108 
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SFRP5 1° GTAGAGTTGTGTTAGGGGAGTTG ACCACTTCCCCTAACCTAAAAT   60 170 
SFRP5 2°  U-CCACAAATTCCCCCTAAACA TGTTAGGGGAGTTGTAGG GTYGTYGGAGYGYG 60 139 
P16-P1 TTTGGTAGTTAGGAAGGTTGT U-ACCTCCCTACTCCCAACC TGGTAGTTAGGAAGGTTGTA TYGYGGAGGAAGGAAAYGGGGY 55 130 
P16-3-2 AGGGGTTGGTTGGTTATTAG U-CCCTCTACCCACCTAAATC GAGGGGGAGAGTAGGTA GYGGGYGGYGGGGAGTAGTATGGAGTYGGYGGYG 55 255 
P16-4-2 GTTTGTAGGGGAATTGGA U-CCTCATTCCTCTTCCTTAACT GGGAATTGGAATTAGGTA GYGTTTYGATTTTTYGGA 55 147 
P16-4-
1ADD U-GGGGAATATATTTGTATTAGATGG CCCAACACATCTTACATTTCTT CCCTTTTTATCCCAAAC RTTCRTAAAT 55 106 
P16-4-
2ADD U-TGTGGTGTATGTTGGAATAAAT TCTCCCAAAATAAAAAAATTACAA AATTACAAAACRTAAAACAC 
CRCRCCCRACCRCTTCTAAATAA
TTTCRAT 55 111 
LINE-1 TTTTGAGTTAGGTGTGGGATATA U-AAAATCAAAAAATTCCCTTTC AGTTAGGTGTGGGATATAGT TTT/CGTGGTGT/CGTT/CGTTTTTTAAGTT/CGGTTTGAAAAG 56  
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Table 2. RT-PCR primers 
Name Forward Reverse MGB-Probes (FAM) Tm (°C) Amplicon (bp) 
tTS tTS-qF1: GGGCTGAAATCATTAATATTTGGATT 
tTS-qR1: 
CCATCCTCAATGGGTGTATGC na 60 71 
ACTB 4333762F (Applied Biosystems)   
PCNA Hs99999177_g1 (Applied Biosystems)   
DNMT1b Hs00945901_g1 (Applied Biosystems)   
DNMT3B1 Hs01003405_m1 (Applied Biosystems)   
GAPDH ATGGAAATCCCATCACCATCTT CGCCCCACTTGATTTTGG GGAGGCCGATCCAG   
EGFP EGFP-415F: GGGCACAAGCTGGAGTACAAC 
EGFP-486R: 
GATGCCGTTCTTCTGCTTGTC 
EGFP-440T: 
ACAGCCACAACGTCT  71 
DNMT3B-V5His 3B-V5His-qF1: CTGAAGGACTACTTTGCATGTGAAC 
3B-V5His-qR1: 
CCGCCACTGTGCTGGATAT 
3B-v5His-qP1: 
AGTGTGGTGGAATTC  78 
HA-DNMT1 HA-DNMT1b-qF1: GGGATACCCATACGATGTTCCA 
HA-DNMT1b-qR1: 
TACGCGCCGGCATCTC 
HA-DNMT1b-qP1: 
ATTACGCTGCGTCGAC  56 
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Table 3. PCR primers for subcloning to constructs 
Name Forward Reverse Tm (°C) Amplicon (bp) 
Zeocin 
Zeo-cdsF1 (AvrII)  
tggaggCCTAGGcttttgcaaaaagctcccgggagcttgtATGGccaagttg
accagtgccgt (from pcdna3.1)                              
Zeo-cdsR1 (BstBI)  
gaccTTCGAATCAgtcctgctcctcggccac 
 
60 415 
tetO 
tetO-F (5’EcoRV, BstXI, SacI, AvrII, XhoI--) C inserted 
cggcGATATCCCAGCACAGTGGctgGAGCTCatgcCCTA
GGCTCGAGccggaattgaaga (from pSIREN-tetO-shRNA(P)) 
tetO-R (5’ NheI, AflII--) 
cggcGCTAGCatgcCTTAAGtatgaccgtacac 60 303 
3Motif 3MF-F (5’EcoRV, BstXI--) cggcGATATCCAGCACAGTGGctcttgctctgtcacc 
3MF-R (SacI) 
cggcGAGCTCatcccagctacttg 60 140 
RILWH 
RIL-whole-MF1 (5’EcoRV-universal BT primer) 
tagtGATATCggcctgcaggccaggtccagcCTGTGCAGACAGG
GAGGTG  
RIL-whole-MR1 (5’SacI, BstXI,) 
gcgGAGCTCcagCCACTGTGCTGGGTGACTGAGGT
CGTGAATG 
60 1397 
RILUP RIL-whole-MF1 
RIL-up-MR1(5’SacI, BstXI,) 
gcgGAGCTCcagCCACTGTGCTGGGGGCTGCCCCA
GCTCAGA  
60 356 
RILCEN 
RIL-cen-MF1(5’EcoRV-universal BT primer) 
tagtGATATCggcctgcaggccaggtccagcATGAGGAGGTATC
TGAGCTG 
RIL-cen-MR1(5’SacI, BstXI,) 
gcgGAGCTCcagCCACTGTGCTGGCCTTCAAGCCT
CGGATACAC  
60 663 
RILDN 
RIL-dn-MF1(5’EcoRV-universal BT primer) 
tagtGATATCggcctgcaggccaggtccagcCCCTGTGTATCCGA
GGCTT 
RIL-whole-MR1 60 471 
Tr-pINSL6 INSsubF (NheI and XhoI) Gcatgctagctggccaggatctctcgagcccacaaatgga 
INSsubR (KpnI) 
CCGCGGTACCGTCGACTGCAGAATT  60 540 
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Table 4. PCR primers for confirmation of integration 
Confirmation of integration 
For which For what Forward Reverse Tm Amplicon (bp) 
Break 
point on 
vector 
HCT/ZEO-1D2 On vector ZEOSET1F ZEOSET1R 60 949(none=right) close to 6090 
 Vector-loci ZEO1D2F: AGGCTGCAGCAGACAGTTTC 
ZEO1D2R: 
AAGTTGGCCGCAGTGTTATC 50 >650  
SW/ZEO-1A5 On vector ZEOSET6F ZEOSET6R 60 1192(none=right) 450 
 Vector-loci ZEO1A5F1: CCGTAATGGGATAGGTCACG 
ZEO1A5R1: 
TCCTGGAATGCAGCTCTTTT 60 ~600bp  
SW/ZEO-1A1 On vector ZEOSET3F ZEOSET3R 60 1383(none=right) 4488 
 Vector-loci ZEO1A1F3: CCCGTCAGTATCGGCGGAAT 
ZEO1A1R3: 
GCAGAAACCTGGTGCCTGAA 55 ~700bp  
Integration of pFRT/LacZeo 
Forward Reverse Tm Amplicon (bp) Location 
LacZ-2F: 
GACGTCTCGTTGCTGCATAA LacZ-2R: GACCTGACCATGCAGAGGAT 60 468 Inside Lac 
Tiling primers 
Forward Reverse Amplicon (bp) Location Tm(°c) 
Zeoset1F: ccccctgaacctgaaacata Zeoset1R: gaggccctttcgtcttcaa 949 5165-6113 60 
Zeoset2F: cgaggagcaggactgacac Zeoset2R: ggcagcctatgattggaatg 1251 4166-5416 60 
Zeoset3F: gtgcacggcagatacacttg Zeoset3R: ttccttcacaaagatccatgc 1383 3125-4507 60 
Zeoset4F: cacccgagtgtgatcatctg Zeoset4R: agtaaggcggtcgggatagt 1386 2001-3386 60 
Zeoset5F: ctggcgtaatagcgaagagg Zeoset5R: cagcgaccagatgatcacac 1270 758-2027 60 
Zeoset6F: gggaaacgcctggtatcttt Zeoset6R: gacagtatcggcctcaggaa 1192 782-905 60 
Zeoset7F: ttttgtgtccctgaatgcaa Zeoset7R: ggcacctatctcagcgatct 1172 5968-7139 60 
Zeoset8F: aagccataccaaacgacgag Zeoset8R: agctcactcaaaggcggtaa 1235 6805-8039 60 
Integration of pCDNA5FRT constructs 
40 
 
Forward Reverse Tm Amplicon (bp) 
GFP-BGHF: tatatcatggccgacaagca GFP-BGHR: gcgatgcaatttcctcattt 60 430 
INS6-GFPF1: gctaccttcgaccacctgag INS6-GFPR1: gaacttcagggtcagcttgc 60 425 
SV40-HYG-F2: cggcctctgagctattccag SV40-HYG-R1: gcagctatttacccgcagga 60 259 
3MF-TETOF1: ccaagtagctgggatgagc 3MF-TETOR1: atgaccgtacacgcctacct 58 335 
RIL-TETOF1: tccagtgtggtggaattctg 3MF-TETOR1 59 
380 +   RILwh 1.8kb 
             RILup 724bp 
             RILcen 1030bp 
             RILdn 839bp 
P16-TetOF1: gccagatatacgcgttgaca P16-TetOR1: gggagtaaactcaagtgaagacg 59 103 
P16-TetOF2: tgtacgggccagatatacgc P16-TetOR2: cttgaggtacctgggatgga 62 237 
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Table 5. Inverse-PCR primers 
Used for Enzymes Steps Forward Reverse Tm (°C) 
HCT116/zeo- 
1D2 
BamHI+BglII 
 1 
INVB3F: 
AGCCGGAAAACCTACCGGATT(3207-
3227) 
INVB3R: 
CCTCAGGAAGATCGCACTCCA  (874-
894) 
~65 
  2 
NVB4F: 
ATGAATGGGAGCAGTGGTGGA 
(4653-4673) 
INVB4R: 
TAACGCCAGGGTTTTCCCAGT (697-
717) 
~68 
SW48/zeo-
1A5 EcoRI + MfeI 1 
INV-7F : 
TGACGCGGTGCTGATTACGA  (3146-
3165) 
INV-7R : 
CGCGTAAAAATGCGCTCAGG  (1169-
1188) 
~65 
  2 
INVB5F : 
GCTGGGATTACACATGGCATGGA  
(3786-3808) 
INV5R : 
TAATTCGCGTCTGGCCTTCCTGT  
(1055-1077) 
~68 
SW48/zeo-
1A1 XbaI + AvrII 1 INV-7F INV-7R 65 
  2 INVB5F INV5R 68 
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Table 6. Chip primer and probes 
Name Forward Reverse Probe Amplicon (bp) 
SiteA TGCTGTATTTGAATCCGACGTT GCCTTGGATGGAAGAACAAATC ATCTGAAAGGAATCCCT 69 
SiteD AACTTCACAAACATATACACTCTGCTGAT GACGGAGCAAGGATGGAGAA CTAGACCGGTGTCCTT 67 
TETO-
INSL GGCGTGTACGGTCATACTTAAGG GGTGAGATAATTTTGCTCAGTTAGGA TCTCTCGAGCCCCTTC 85 
INSL-GFP GCCGACCGCCATTGC ACTGCAGAATTCGAAGCTTACTTAGA TCACAGGAGATCTGC 79 
ACTB TCCCCTCCTTTTGCGAAAA CGGCCAACGCCAAAACT AGCGAGATTGAGGAAGA 78 
GAPDH CTGCTCCTCCTGTTCGACAGT TCACCTGGCGACGCAAA AGCCGCATCTTC 52 
RARB TTGGAAGGAGAACTTGGGATCTT AGGCTTGCTCGGCCAATC CTGGGAACCCCCC 85 
P16 GGGCGGATTTCTTTTTAACAGA CGCCTGCCAGCAAAGG TGAACGCACTCAAAC 57 
LINE-1 ACGGAATCTCGCTGATTGCT CGTTGCCGCCTTGCA AGCAGTCTGAGATCAA 58 
Igf2/H19 
ICR ATTCCACACGTACAGCCGATT AAGGGAGGCCCGTCTCACT TGCGCCATCAGGG 65 
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RNA extraction and Quantitative RT-PCR 
Total RNA from every 107 cells was extracted with 1 ml TRIzol® Reagent (Invitrogen) 
as instructed in the manufacturer protocol, precipitated in 200 µl RNase-free isopropanol and 
resuspended in 30 µl RNase-free distilled water. Further elimination of remnant DNA used The 
DNA-free™ DNase Treatment Reagents (Ambion) and isolated RNA was tmeasured in 
NanoDrop™ 1000 spectrophotometer (Thermo Scientific). The integrity of RNA was also 
tested using 1.5% agarose gel. 
We used two-step quantitative RT-PCR to analyze RNA expression levels. The reverse-
transcription was performed using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) with 2 µg total RNA. The TaqMan® Gene Expression Assay (Applied 
Biosystems) (20 µl reaction/assay) was used to get Ct values for each target region. The 
delta-delta Ct normalized to both control genes (GAPDH or β-actin) and control cells, or 
delta Ct normalized to endogenous controls (GAPDH or β-actin) was calculated to represent 
the relative quantity of target gene expression in experimental samples. The “minus RT” 
controls were also included in every RT-PCR. Details of primers are listed in Table 2.  
Generation of stable single clones with single integration sites 
The general guideline to use the Flp-in system (Invitrogen) is available through the online 
instructions. According to the instructions, after transfection of pFRT/lacZeo into HCT116 
and SW48 and stable selection of single clones with 50 μg/ml zeocin (Invitrogen), PCR and 
β-gal staining were performed to verify FRT integration. Then, tiling primers (Refer to 
primers in Table 5) were used to screen out clones with single integration, and the genomic 
loci were identified through inverse PCR. 
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β-Gal Staining  
The β-Gal Staining Kit (Invitrogen) allows to detect expressed LacZ from pFRT/lacZeo 
in transfected cells. Reactions were performed for 20% confluent cells in each 12-well plate. 
Control wells were also included as for absence of LacZ. For testing the second integration 
by pCDNA5/FRT constructs, control cells were those positive ones from the first integration. 
 
Inverse PCR 
Genomic DNA from each single clone was digested with restriction enzymes (EcoRI and 
MfeI, or BamHI and BglII). Then ligation was performed using T4 DNA ligase (Takara), and 
the product was amplified with primers targeted at pFRT/lacZeo sequence. The amplified 
bands were purified (QIAquick PCR Purification Kit, Qiagen), cloned into TOPO XL vector 
(Invitrogen) and the adjacent sequences were identified through BLAT program. The single 
integration was further validated through amplifying the conjunction between the insert and 
the genomic locus. More details of primers are available in Table 4, Table 5 and Table 6. 
 
Establishment of Flpin-tTS host cells 
To establish tTS-containing host cells, the tetracycline-controlled transcription silencer 
(tTS, Clontech) was transfected and selected with 800 μg/ml G418. The presence of 
functional tTS was verified with RT-PCR and transient transfection of an EGFP vector 
carrying a tetO element under conditions of Dox (+) (2 μg/ml) or Dox (-). The clones with 
highest Dox (+) GFP/Dox (-) GFP ratio were selected as tTS-containing host cells. 
 
Flow cytometry 
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All cells for flow cytometry were to test GFP expression. Log-phase cells from each 12-
well or 6-well culture were trypsinized and suspended in 1-ml media. When dead cells 
needed assessment, propidium iodide (f.c. 1 µg/ml) was added to do staining. FACSCalibur 
(BD Biosciences) was manipulated as the manufacturer’s protocol. 
 
Construction of transgenes, homologous recombination and clonal selection 
The transgenes consist of a reporter EGFP, a pINSL6 promoter, a tetO element, the 
fragment of interest and the backbone from vector pCDNA5/FRT (Invitrogen). All fragments 
were amplified using PCR SuperMix High Fidelity (Invitrogen), digested with certain 
restriction enzymes (NEB), subcloned to contruct transgenes and sequenced for correct 
sequences (see primers in Table 3, Table 4 and Table 5).  
To make homologous recombination mediated by FRT sites, pCDNA5/FRT constructs and 
POG44 (for flippase expression) were co-transfected into characterized Flp-in host cells with 
1:9 ratio (w/w) and stably selected with hygromycin B (150 µg/ml) (Invitrogen) for 10 days. 
Correct single clones were confirmed by PCR amplification of inserts, zeocin-resistance (50 
μg/ml, 10 days), and β-gal staining.  
 
Drug treatment 
For inhibition of DNA methylation and reactivation of GFP, we used 200 nM 5-Aza-2-
deoxycytidine (DAC, Sigma) and/or 800 nM trichostatin A (TSA, MP Biomedicals). Cells 
were split 24 hours before experiment, and given one of the following treatments. (1) DAC 
was given every day for 96 hours, and media were replaced every day; (2) TSA was added at 
the last 24 hours; (3) combined treatment of the above DAC and TSA. Flowcytometry 
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(FACSCalibur, BD Biosciences) was performed to detect GFP expression as instructed by 
the manufacturer. 
 
ChIP analysis 
The procedures of chromatin immunoprecipitation (ChIP) assays were adapted from the 
online protocol. 1×106 cells were used for each immunoprecipitation. Antibodies (10 µg) 
used are IgG (ab6709, Abcam), H3 (ab1791, Abcam), H3K4me3 (07-473, Millipore), 
H3K9ac (07-352, Millipore), H3K27me3 (07-449, Millipore), and H3K9me3 (ab8898, 
Abcam). Following immunoprecipitation, qPCR was performed in 7500 Real-Time PCR 
System (Applied Biosystems) to get Ct values. All the enrichment of histone marks was 
normalized to H3 (percent of H3) and the nucleosome density measured by the H3 
occupancy (percent of input) was calculated against the 1/50 input control. Primers and 
probes are listed in Table 8. 
 
Protein extraction and western blot 
(5~10) × 106 of cells were lysed in cold 1 ml RIPA buffer (Thermo Scientific) 
supplemented with protease inhibitor cocktail tablet (Roche) and PMSF (Fisher). The 
supernatant was transferred and aliquoted into new tubes. Each aliquot of cellular protein (50 
~100 μg) was boiled for 5 min in sample-loading buffer (Biorad) and then separated through 
SDS-PAGE gels (Biorad) depending on the sizes of target proteins. Wet-traferred onto PVDF 
membranes (Biorad), the samples were either blocked with 5% nonfat milk in PBST or 1% 
BSA in PBST depending on the chemical properties of the antibodies. Primary antibodies 
used are anti-DNMT1 (Abcam), anti-DNMT3B (IMG184, Imgenex), anti-HA (Sigma), anti-
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His (Invitrogen) and anti-ACTB (Sigma). The secondary antibodies were HRP-conjugated 
anti-rabbit (Amersham Pharmacia Biotech) or anti-mouse (Biorad). Bands development used 
Pierce ECL Western Blotting Substrate (Thermo Scientific) and exposed on X-Ray imaging 
film (Fisher). 
 
DREAM library preparation 
High quality of genomic DNA was confirmed by running 500 ng in 0.8% agarose gel 
before any further treatment. 5 µg of such unbroken genomic DNA was mixed with 0.2 ~ 0.5 
ng spiked DNA for digestions with restriction enzymes. The spiked DNA comprised a set of 
PCR-amplified fragments from non-human DNA which were in vitro methylated at CpG 
sites by the M.SssI methylase to several magnitudes of 0% ~ 100%. The DNA mixture was 
first digested by SmaI (Fermentas) for 3 hrs followed by overnight XmaI (NEB) digestion. In 
the second day, column purified products had to be heated at 65ºC for 3 min, and cooled 
down to free concatenated overhangs. Then Klenow fragment (3’→5’minus) (NEB) was 
added to the above digested DNA sample for filling the overhangs and adding “dA” to the 3’-
tails. The second purification using QIAquick MinElute PCR purification kit (Qiagen) was 
followed by ligation of 1:50 diluted Solexa Paired Ends Adapters (PEA) (25 µM). 
Afterwards, selected products with the size of 250 ~ 500 bp using 2% agarose gel were 
divided into 2 even slices and purified separately with Qiagen Gel Extraction kit. In order for 
the cluster station to create clonal clustering of single molecules, PCR amplification (18 
cycles) with the Solexa paired-end PCR primers was required (iProof HF master mix, 
BioRad). Products were further purified with Agencourt AMPure beads and two size ranges 
were confirmed in 2% agarose gel, or more accurately on Agilent 2100 Bioanalyzer using 
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Agilent DNA 1000 kit, which would tell the primer-dimer contamination as well. NanoDrop 
1000 was used to determine the concentration.   
 
DREAM library validation — Pyrosequencing and TA cloning 
Two other quality validation steps were also needed. Diluted DNA from each library was 
amplified with PCR and examined for pyrosequencing. The target regions were within the 
component fragments of the spiked DNA which had ranges of methylation percentages (0% 
~ 100%). The good quality was demonstrated by the close match between pyrosequencing 
results and the expected percentages. 
The other validation is to make TA clones using 2 µl of each library. 12 clones with correct 
insert size were sent for sequencing and the ratio of XmaI/(SmaI + XmaI) would help 
estimate the average methylation of each sample. How to perform pyrosequencing and TA-
cloning has been mentioned previously. 
 
Data processing and statistics 
All next-generation sequencing datasets are received after pre-analysis by DNA 
sequencing core facility in M.D. Anderson Cancer Center. Excel, Graphpad and R-program 
are major softwares used in data processing and statistical analysis. 
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Chapter 3 
Establish a site-specific integration system with enforced transcriptional 
repression 
Introduction 
How de novo DNA methylation is triggered still remains a question. There are basically 
two strategies to study this question. One is to mimic the process of normal embryonic 
development or malignant progression induced by certain inner- or extra-cellular conditions. 
The other is to observe de novo methylation events in transgenes. Currently, most 
investigations were focused on the differentiating course of ES cells. Methylation seeding on 
APRT gene was observed  in mouse embryonal carcinoma cell (65-68), and targeted de novo 
methylation in the enhancer and promoter regions of Oct-4 was detectable 2 days after the 
wild-type ES cells induced with retinoic acid (RA), followed with throughout spreading into 
its regulatory region, although Oct-4 does not have a CGI in its promoter (110).  Compared 
with ES cell, seeding events are still barely studied in somatic cells, probably because these 
events require longer observation window than usually expected. For example, it took as 
many as 87 passages for P16 promoter (with a CGI) in HCT116 DKO (DNMT1-/-; 
DNMT3B-/-) to get fully remethylated (111). Nonetheless, remethylation of P16 indeed 
indicated that cancer cells still keep active de novo methylation.  
There are disadvantages of both strategies. For the induction way, when the cis- or trans- 
elements need investigation, it would be complex to do multiple gene deletions. While for the 
transgene way, transfected genes generally remain unmethylated, even if introduced into 
cells where the endogenous ones are methylated. For the glutathione-S-transferase gene 
(GSTP1), hypermethylation did not occur in exogenous GSTP1 shuttles and both silencing 
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by mutations of transcription factor binding sites and pre-methylation were required for high 
levels of DNA methylation to be seen after spreading (112). The experiments using mixed 
stable clones to observe de novo methylation were neither ready to get replicable changes. 
One problem in all these experiments is the variability associated with insertion site effects.  
Thereafter, we generated a site-specific integration system in order to test different aspects of 
methylation seeding and spreading as relevant to tumor-suppressor gene silencing in cancer. 
By constructing two different integration sites in two colorectal cancer cell lines (SW48 and 
HCT116) due to their high background of DNA methylation (113, 114), and constructing two 
comparable groups of host cells with different local repression strength for each case through 
introducing a defined regulator, the tetracycline-controlled transcription silencer (tTS, a tetR 
DNA-binding domain fused with a KRAB domain), the trans-regulatory factors caused by 
transcriptional repression, genomic loci and/or cell line could be tested. By controlling the 
fragments of transgenes, the cis-sequences could be examined, too. 
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Results 
Construction of flp-in host cells 
Our aim was to evaluate the possibility of de novo DNA methylation in cancer cell lines 
through exogenous sequences without in vitro methylation. For this aim, an Flp/FRT-
mediated integration system was utilized to make each transgene integrated into the same 
single genomic locus due to our concern for the position effects arising from multiple or non-
ubiquitous chromatin environment. The basic steps are schematically described in Figure 7 
where each step is indicated with Roman numerals (I, II and III). 
In step I, a vector (pFRT/LacZeo) with an FRT site was introduced into cell lines and 
integration was screened by constructive expression of the reporter gene (LacZ) and presence 
of a sequence close to FRT in stable single clones (Figure 8).  Two colorectal cancer cell 
lines, SW48 and HCT116 were chosen to make transfection because of their higher 
methylation background as shown before (113, 114).  
The presence of FRT is not sufficient to indicate single integration. In order to identify 
clones with possible single integration, a screening method was designed by using tiling 
primers for pFRT/LacZeo. The assumption was that if single integration exists, there is one 
break point on the vector, so clones which show negative amplification with only one primer 
set are much definitely inserted into a single locus. Nonetheless, clones with negative 
amplification for multiple primer sets, especially those sequentially located on the vector, are 
also possible ones with single integration, although less likely and could not be excluded 
absolutely. Because primer sets are overlapped at both ends, there are cases that break is 
inside the overlap or only partial vector is inserted. Figure 9 shows the primer sets and 
representative results for some primer sets. SW48/Zeo-1A5 and SW48/Zeo-1A1 were later 
found as clones with single integration. 
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We characterized the genomic locus for clones with possible single integration through 
inverse PCR. Restriction enzymes with compatible ends were used to increase the frequency 
of digestion and generate shorter fragments for the convenience of cloning and sequencing. 
Figure 10 shows the general process of this method and two clones with identified sites. The 
site for HCT116/Zeo-1D2 was on Chr3q13.31 inside one intron of ZBTB20, and the break 
point on the vector was also defined by aligning the sequencing results with both the vector 
and the human genome (Hg18) (Blast2, NCBI and BLAT, UCSC). Therefore, two validation 
PCR reactions could confirm one break on the vector and the correct genomic locus. One 
used the tiling primer Set3 and the other used primers targeted at the linking region of the 
insert and the genome, so negative amplification for the former and positive for the latter 
proved the above finding. With the same method, another single clone, SW48/Zeo-1A5 has 
the integration within an exon of CD36 on Chr7q21.11. SW48/Zeo-1A1 also has the 
identified site on Chr2p25.1 (not shown). For convenience, we rename SW48/Zeo-1A5 as 
SW48A and HCT116/Zeo-1D2 as HCT116D in following results (Table 7). 
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Figure 7. Schematic description of establishing a site-specific integration system. The 
entire system was established using three steps. I, single integration of FRT; II, expressing 
tTS to generate tTS-containing host cells; III, FRT-mediated homologous recombination of 
transgenes with subcloned fragments derived from the RIL or P16 promoter. After I and II, 
for each genomic locus in each cell line, a parallel of flp-in host cells were generated (with 
and without tTS) so as to examine the influence of local transcriptional repression on DNA 
methylation. pINSL6 refers to the INSL6 promoter, which contains a CGI and two short 
LINE elements upstream.   
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Figure 8. Transfection of pFRT/LacZeo into cell lines. (A) Linear depiction of the 
vector pFRT/LacZeo. Primer P1 is used to PCR one region close to the FRT site. 
Restriction sites for enzymes (BglII, BamHI and EcoRI)  and primer P2 and P3 are also 
indicated for the subsequent inverse PCR. (B) and (C) Bands amplified using primer P1 to 
demonstrate the presence of the FRT after stable transfection in single clones selected under 
zeocin. (D) β-gal staining results showing the expression of LacZ in the above selected 
clones. All these clones in B and D are from HCT116 as representatives and those in C are 
from SW48.   
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Figure 9. Tiling primers to screen out possible single clones with single integration sites. 
(A) A vector graph of the circular pFRT/LacZeo. The tiling primers are shown as curved 
arrows with names of Set1 to Set8 that are overlapped at both ends. Some restriction sites are 
also indicated for inverse PCR. (B) Examples showing PCR results using primer Set6 and 
primer Set3 in transfected single SW48 clones. The negative amplification in only one primer 
set would indicated possible single integration.  
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Figure 10. Identify and validate the single integration site of flp-in host cells. (A) 
Graphical description of inverse PCR. (B) and (E) show the genomic loci for 
HCT116/Zeo-1D2 and SW48/Zeo-1A5. (C) Validation of the break point on the 
pFRT/LacZeo vector in HCT116/Zeo-1D2 using one tiling primer Set3. (D) Validation of the 
insertion to the indentifited genomic site by amplifying the conjunct of the vector and the 
site. The appearance of one band for HCT116/Zeo-1D2 confirmed the correct integration. (F) 
Similar validation as in (D), but for SW48/Zeo-1A5.  
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Table 7. Characterization of the single integration site in flp-in host cells. 
Single clones Location Position(hg18) Nearby genes Orientation Elements 
HCT116D Chr3q13.31 115911000-115913000 ZBTB20 + Intron 
SW48A Chr7q21.11 80138271 CD36 - Exon 
SW/zeo-1A1 Chr2p25.1 8823363 KIDINS220 - Intron, SINE 
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Heterochromatin environment of the insertion sites 
Constructing a single integration site for every transgene would equalize the experimental 
background, yet it does not rule out the position effect variegation (PEV) in transgene 
methylation which has been suggested by controversy from prior trials. We would like to use 
the locus with permissive environment for de novo DNA methylation to occur, and the 
association of DNA methylation with heterochromatin suggested the locus should not be 
close to an actively transcribed region. Therefore, we examined the epigenetic status around 
the identified loci including DNA methylation and histone marks (H3K4me3, H3K9ac and 
H3K9me3). SiteA refers to the locus in SW48A and SiteD is in HCT116D. Both loci were 
within inactive chromatin regions that had very high levels of DNA methylation (SW48, 
87.6%±4.00%; HCT116, 98.4%±0.80%, mean±SEM) (Figure 11) and lacked active histone 
marks examined here (H3K4me3 and H3K9ac) in comparison to enriched levels of active 
marks for ACTB and GAPDH (Figure 12). Although H3K9me3 was not enriched around 
SiteA or SiteD, they may have other marks and still could be called as heterochromatin. The 
H3 occupancy at SiteA and SiteD was also examined by normalization to the corresponding 
input, turning out that the absence of marks was not due to unloaded H3.  
It is also necessary to know if any sequence of pFRT/LacZeo could bring any significant 
DNA methylation to the area. Pyrosequencing showed that the inserted LacZ region did not 
gain much DNA methylation in any clone (SW48A, 5.4%±1.75%; HCT116D, 4.7%±1.65%), 
precluding the possibility of methylation recruitment caused by sequences from the first 
construct (Figure 11). Consequently, there are two flp-in host cells of characterized local 
properties (copy number, location, and transcriptional activity) available for subsequent 
homologous recombination. 
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Generation of flp-in/tTS host cells 
Given that the integrated sequences contain potential promoters, we wished to introduce 
further transcriptional silencing into this system. We therefore inserted a defined regulator, 
the tetracycline-controlled transcription silencer (tTS, a tetR DNA-binding domain fused 
with a KRAB domain) to generate a parallel group of host cells (SW48A/tTS and 
HCT116D/tTS), where we could get the effects of strengthened repression. After transfection 
of tTS to SW48A and HCT116D, expression of tTS was analyzed for each stable single clone 
selected with G418 in comparison to the internal control β-actin. Since Dox can prevent tTS 
from binding the response element (tetO), to select the clones with functional tTS, a tetO-
containing EGFP construct was transiently transfected into each tTS-expressing clone under 
two parallel conditions, Dox (+) and Dox (-). After 72 hours, we used flow cytometry to test 
GFP expression, and the ratio of Dox (+) to Dox (-) was calculated for each clone. The 
clones with highest ratios were chosen as flp-in/tTS host cells. Thus, for each integration 
event, there would be two kinds of local conditions in regard to transcriptional repression 
(Figure 13).  
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Figure 11. DNA methylation of the environment for homologous recombination. (A) 
Pyrosequencing results showing the endogenous methylation of the characterized integration 
sites (SiteA for SW48A and SW48A/tTS; SiteD for HCT116D and HCT116D/tTS). 
Bisulfite-treated genomic DNA from SW48 and HCT116 was used as template. Two 
separate pyro-assays were designed for 1-kb range to each site and average methylation was 
calculated. Error bar, SEM. (B) Methylation of the LacZ in flp-in host cells (SW48A and 
HCT116D). Pyro-assays were designed inside the coding sequence of LacZ. 
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Figure 12. Chromatin signatures of the integration sites in SW48 and HCT116. ChIP-
qPCR results showing (A) the enrichment for histone marks (H3K4me3, H3K9ac and 
H3K9me3) and (B) H3 occupancy at the integration sites. ACTB and GAPDH as the control 
regions for active marks, and RARB as the negative control region. In (A), average Ct-values 
of histone marks from technical duplicates were normalized to those of H3. In (B), 
normalization was calculated to the input.  
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Figure 13. Generation of flp-in/tTS host cells. (A) Graphical description of the mechanism 
for a transcription repressor (tTS) to induce formation of robust local heterochromatin. The 
KRAB domain is responsible to bind KAP-1 which recruits a modification complex 
composed of histone methyltransferase, histone deacetylase, chromatin remodeling factors 
and heterochromatin protein-1. TetR is the peptide to bind the tetO element present in a 
promoter. Hence, tTS could be inducible to control repression under Dox treatment. (B) 
Stable selection of single clones of flp-in/tTS host cells by RT-PCR. RNA expression of tTS 
and internal control (β-actin) were analyzed for every single clone selected by G418. (C) 
Flowcytometry to validate the functional tTS in SW48A/tTS and HCT116D/tTS. Parallel 
wells of stable single clones of tTS-expressing flp-in host cells were transiently transfected 
with a tetO-containing EGFP construct under the presence or absence of Dox treatment. GFP 
fraction was measured 48hr after transfection and the clones with the highest ratio of Dox (+) 
to Dox (-) were used as tTS-containing flp-in host cells.  
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Discussion 
The goal of this project is to generate a system that could investigate several aspects 
engaged in de novo DNA methylation, specifically on CGI-promoters. The aspects we are 
interested in are (1) repetitive elements adjacent to CGI-promoters that are frequently 
hypermethylated in cancer cells; (2) the extent of transcriptional repression in regulating 
DNA methylation; (3) the effect of genomic position/cell line on DNA methylation. Aspect 
(1) would be represented in organization of the transgenes, aspect (3) needs construction of a 
model system, while aspect (2) would require both of the above manipulations. Thus, we first 
established such a system to complying with the requirements for aspect (2) and aspect (3), 
of which the genomic position has been characterized and an ectopic transcriptional 
repressor, tTS, is expressed.  
As known, transgene expression is influenced by sequences proximal to the integration 
site which is usually random in the genome. The influence could be either to the positive or 
negative trend, for example, the integration to a heterochromatin would generate silencing in 
a proportion of cells expected to express the transgene (115). DNA methylation of transgenes 
probably is subject to the same influence of position effect. Proviral transfection into mice 
could be inactivated by de novo DNA methylation at a later stage (116), however, the study 
of the glutathione-S-transferase gene (GSTP1) gene only observed sporadic methylation in 
GSTP1 shuttle vectors (112). A further study compared random integrated BLK sequence 
with homologously recombined one, and the de novo DNA methylation did show the 
influence out of position effect.  
Therefore, in order to get reliable results, all the transgenes have to be examined under 
the same vicinity, and a site-specific integration system using Flp/FRT was utilized. In this 
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system, transgenes are transfected into host cells containing a FRT site which would mediate 
homologous recombination in the help of the flippase (Flp). For the flp-in host cells, we 
characterized the single presence of FRT and its integration site. Inverse PCR itself may not 
determine the copy number of the insert, but combined with tiling primers and validation 
experiments, we had identified two host cells from SW48 and HCT116. Due to the concern 
of position effect, we would like the integration site to reside in a genomic area with the 
property of heterochromatin. So characterization of DNA methylation and histone 
enrichment were examined further.  Both sites in flp-in host cells (HCT116D and SW48A) 
have average methylation levels above 80%, and lack the most common active histone marks 
(H3K4me3 and H3K9ac), suggesting these sites are not actively transcribed regions at least. 
That is to say, there probably would be no negative effect from the vicinity on transgene 
methylation if these two host cells are used. 
However, we were still not sure to what extent these loci would influence transgene 
methylation. To ensure robust heterochromatin adjacent to trangenes, in parallel to the flp-in 
host cells, we constructed flp-in/tTS host cells (SW48A/tTS and HCT116D/tTS) by stably 
expressing a defined transcriptional repressor, tTS into the above flp-in cells. The 
tetracycline-controlled transcription silencer (tTS) is a fusion protein composed of the tetR 
DNA-binding domain and a KRAB domain. It is usually used in inducible expression 
system, and here we are employing its sequential recruitment of the H3K9-specific histone 
methyltransferase (e.g. SETDB1), HP1, and the histone deacetylase (HDAC)-containing 
complex via KRAB-KAP1 cooperation (117, 118). Hence, even over a range of euchromatin, 
a highly compact heterochromatin patch can be generated and maintained for quite a few 
siblings. This provides an environment permissive for DNA methylation to occur. There is 
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another place to permit DNA methylation is the promoter used in transgenes, which would be 
discussed in the following Chapter. 
Overall, we first established a site-specific integration system with enforced local 
repressive status to allow DNA methylation to occur. 
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Chapter 4 
Repetitive elements and strengthened local heterochromatin enhanced de 
novo methylation in a promoter-CGI 
Introduction 
The triggers for de novo DNA methylation are not defined clearly so far. If DNA 
methylation does not happen globally which is suggested by unequal accessibility of DNMTs 
to genome regions, then local sequences have to signal for DNA methylation directly or 
indirectly (2, 23, 24). Trans-regulatory elements out of various origins are suggested in 
determining the preference of DNMTs. The biochemical property of DNMTs might 
predispose their tendency of binding specific motifs, but transcription factors, enzymes for 
histone modifications, chromatin remodeling factors and even RNAi are a lot more likely to 
set up flexible patterns of DNA methylation under various physiological and abnormal 
conditions. Then, DNA sequences would signal indirectly and recruit complexes of 
regulators prior to stable cytosine methylation. In this sense, the sites susceptible to DNA 
methylation would also possibly be signals to set up this epigenetic memory.  
We have established the site-specific integration system to transfect constructs with 
sequences out of highly methylated genomic areas, especially those around CGI-promoters. 
DNA methylation patterns of such a few CGI-promoters (p16INK4A, MLH1, MGMT, 
CDH1, etc) have been mapped before showed multiple repetitive elements adjacent to a 
“trench” of methylation in CGIs, and they are consistently methylated in both normal and 
malignant cells. Presumably, repetitive elements have something to do with preferential 
DNA methylation. DNA repeats have long been suspected to be involved in chromatin 
nucleation, at least under certain circumstances in yeast, filamentous fungi and plants (119, 
120). Moreover, Turker M.S. and colleagues identified two upstream B1 repetitive elements 
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as cis-signals for de novo methylation of mouse Aprt gene on the X-chromosome (65-68). 
Therefore, we investigated the methylation sensitivity of fragments from CGI-promoters 
including repetitive elements as constructed in transgenes.  
Another concern is related with local status permissive for DNA methylation. It is 
assumed here that transcriptional repression is predominant to DNA methylation as shown 
before (83, 84).We have selected single integration sites for transgenes and imposed a 
repressor to construct a comparison as to repression strength. As well, we also used a 
promoter which is silenced endogenously, since promoters such as CMV and SV40 probably 
would tend to get strong transgene expression and interfere with DNA methylation.  
By combining several aspects into our study system, we were able to observe methylation 
seeding events and examined the effect of repression and repetitive elements on methylation 
spreading into the promoter-CGI. 
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Results 
Mapping the methylation patterns of RIL (PDLIM4) promoter 
RIL (PDLIM4) was originally identified as a new gene in normal rat fibroblasts and 
downregulated in H-ras transformed derivatives (121). This gene, later mapped to human 
chromosome 5q31.1, contains a LIM domain and a PDZ domain, implicating its possible 
interaction with other LIM proteins or itself in cytosolic trafficking. MCA/RDA is a powerful 
tool that allows PCR amplification and cloning novel CpG islands of genes that are 
hypermethylated in cancer. Previous results in our lab have found frequent hypermethylation 
of RIL in multiple tumor cell lines (almost all colon cell lines and some leukemia cell lines) 
and primary tumors (colon and leukemia/lymphoma), and its close association with loss of 
expression, which could be reversed by 5-aza-dC treatment in methylated cell lines. Re-
expression of RIL led to suppression of growth and clonogenicity in vitro and sensitivity to 
apoptosis, which suggested RIL as a candidate TSG (109). 
The CpG island (-347bp to +427bp from TSS) of RIL covers its promoter region, the first 
exon and part of the first intron. Long and short alleles of RIL have been characterized in 
RIL promoter from sequencing of large populations of normal (blood and colon) and tumor 
(colon, AML and CML) samples. The polymorphism is located near a CGG repeat sequence 
adjacent to the transcription start site. The long allele has a 12-bp insert 
(CGGCGGCGGCTC) and a substitution of T to G 3 bases upstream of the insertion site in 
the short allele. The insertion of the long allele was shown to bind with Sp1 and Sp3 
transcription factors in vitro, contributing to the differential methylation of the two RIL 
alleles in tumors as a protective machinery (122).   
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We further compared the methylation of the regions surrounding the CGI in normal and 
tumor cells to find which area the methylation is spread from. We bisulfite-sequenced the 
region of -722 to +630 from TSS (25, 23 and 18 CG sites with three separate reactions) in 3 
leukemia cell lines (CEM, KG1 and HEL), 4 normal blood samples, and 6 colon tumor 
adjacent samples. Comparing the methylation levels across the whole region, we could see 
two clear boundaries, upstream and downstream of the CGI, showing drops at DNA 
methylation. The upstream 11 CpG sites (-689 to -413) and downstream 17 CpG sites (+238 
to +586) are kept densely methylated even in normal blood (average methylation density, 
82.2±11.6% for upstream and 73.6±17.7% for downstream) and tumor adjacent colon tissues 
(average methylation density, 80.5±14.6% for upstream and 76.2±12.1% for downstream), 
compared with those in the CGI (17.6±10.0% in blood and 20.2±15.0% in tumor adjacent 
colon tissues), indicating the possible protective machinery at the boundaries, and the 
candidate de novo methylation originated from the surrounding areas on the other hand 
(Figure 14). This methylation pattern of RIL promoter is very similar with those found in 
genes like p16, VHL and CDH1. The common feature also involves repetitive elements 
juxtaposed to the promoter CpG island, as in RIL a LINE (-629 to -510) located within the 
consistently methylated upstream region.  
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Figure 14. Mapping the methylation pattern of RIL promoter by bisulfite sequencing. 
(A) Schematic RIL promoter region to be investigated. Bars, the CpG sites around -722bp to 
+630bp from the transcription start site (TSS, 0). Positions of bisulfite sequencing are shown 
in numbered rectangles. (B) The methylation patterns of RIL promoter in cancer cell lines, 
normal blood and normal colon tissues.  
 
  
 
73 
 
Construction of transgenes 
After establishing the host cells, transgenes were introduced into the FRT site by flippase 
(Flp)-mediated homologous recombination. We made constructs composed of a reporter 
(EGFP), the Insulin-like 6 promoter (pINSL6), a tetO element, and fragments of interest 
(Figure 15). The INSL6 promoter is a CGI-promoter which is methylated in somatic cells 
including many cancer cell lines (108), and has two short LINE elements (L2, 89bp, 4 CGs; 
L4, 52bp, 1 CG; between L2 and L4, 13bp, 1 CG) upstream of its CGI. TetO is the response 
element to tTS binding in the absence of Doxycycline (Dox), and here was located upstream 
of the pINSL6. We chose RIL (PDLIM4) and P16 (CDKN2A) promoter regions because 
they have consistently methylated repetitive elements (an upstream LINE for RIL; three 
upstream SINEs and one downstream SINE for P16) surrounding the CGI. The fragments of 
interest (Figure 15) include the entire RIL promoter region (RILWH, TSS-713 to +664, 
1421bp, 96 CGs), or isolated fragments containing the hypermethylated upstream (RILUP, -
713 to -378, 336bp, 11 CGs), central (RILCN, -406 to +237, 643bp, 66 CGs) or downstream 
(RILDN, +214 to +664, 451bp, 20 CGs) regions. In the case of P16, fragments are originated 
from three upstream SINEs (P16UPF, forward orientation as in the genome, 980bp; P16UPR, 
reverse) and one downstream Alu (P16DNF, forward, 511bp; P16DNR, reverse; P16DNF3, 
three tandem forward copies, 1485bp; P16DNR3, three tandem reverse copies). We selected 
stable clones using a second marker (Hygromycin B) for only 10 days, as our observations 
indicated selection would confer a pressure for clones to remain unmethylated. 
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Figure 15. Construction of trangenes. (A) Graphical organization of transgenes for 
homologous recombination. Fragments were from RIL promoter, p16INK4A promoter and 
control without any fragment (No-frag). (B) PCR amplification of recombined transgenes. 
Primers SV40-hygro and INSL6-GFP were designed to show correct connection of the first 
vector pFRT/LacZeo and the recombined transgenes. Representative stable single clones 
were shown here. 
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Figure 16. Continuous selection populated unmethylated clones. The vector graph 
indicates two constructs (without tetO) transfected into HCT116D host cells and selection 
with hygromycin B was present until the fourth month, and culture continued for another 
three month (stopped at the sixth month). Bars, the average methylation of all covered CG 
sites by bisulfite cloning/sequencing, and primers are shown in the vector graph. 3M-INS6, 
three motifs located in front of pINSL6; INS6, pINSL6. UP, the upstream primers; DN, the 
downstream primers. 
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Continuous culturing under selection pressure populated unmethylated clones 
Stable single clones are usually under low concentration of selection drug to keep 
effective expression of transgenes. However, we have found that this contiguous culturing 
under selection pressure would play the opposite role in regard to our purpose of observing 
DNA methylation. This was seen in our preliminary examination by transfecting constructs 
with pINSL6 and 3Motif-pINSL6 into HCT116D. The first three months of culturing were 
under selection of hygromycin B, and all single clones showed no more than 8% methylation 
at the examined pINLS6 by bisulfite-sequencing; while another three months culturing 
without hygromycin B did not elevate regional methylation, and the  maximum methylation 
of the same regions was still less than 14% (Figure 16). Replacing pINSL6 with CMV or TK 
promoter also seemed to be refractory to promoter methylation (not shown here). 
Accordingly, these results confirmed that active transcription of the promoter would not 
facilitate DNA methylation. 
 
Unequal silencing speeds of transgenes in flp-in and flp-in/tTS cells 
Following stable transfection of constructs, we first took a look at the changes of GFP 
expression along the time points from the second to the fifth month. In SW48A and 
HCT116D which do not express tTS, it took around four months for GFP to be undetectable 
in most transgenes, while in host cells without tTS the GFP fraction already went down to 
almost 0% at the earliest sampling time. Apparently, tTS in the host cells was functioning 
effectively as shown before (Figure 13) and greatly enhanced GFP suppression. Moreover, 
the exogenous pINSL6 itself was gradually suppressed in host cells without tTS (SW48A and 
HCT116D). However, culturing flp-in/tTS cells in media with Dox could not retain the same 
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GFP expression as in tTS (-) cells. In HCT116D/tTS, Dox restored GFP expression but to a 
lower level than expected; in SW48A/tTS, Dox treatment starting from 2nd month after 
transfection induced little GFP (Figure 17), suggesting that the KRAB-effect had become 
permanent. 
 
De novo DNA methylation center in transgenes 
To test DNA methylation, after transfection and selection we did each analysis 
starting from the first month (for HCT116D and HCT116D/tTS) or the second month (for 
SW48A and SW48A/tTS, which grow more slowly), and repeated the same measurement at 
different time points till the fifth month. The methylation patterns were mapped by bisulfite 
pyrosequencing of several regions shown in Figure 18. Over the examined tetO-pINSL6, 
there are three CG sites (region A) located in the proximal LINE (L2) of the INSL6 promoter 
which demonstrated higher sensitivity to DNA methylation than those in the other regions. 
Take the construct containing only the pINSL6 (No-frag) for example, in SW48A/tTS cells 
of the second month, the average methylation of region A reached 73.6%, which was much 
higher than the other LINE (L4) (region D, 8.0%), the CGI (region C, 7.5%) or the tetO 
(region E, 5.1%). Therefore, these three CG sites were designated as methylation “hotspot”. 
The CG sites between the CGI and the hotspot (region B) achieved an intermediate 
methylation level of 23.3%, suggesting that it may be a “transitional” region in methylation 
spreading. Furthermore, bisulfite sequencing was performed in the same samples (from the 
2nd month) to view the methylation status of every CG site in the examined INSL6 promoter 
(TSS-918 to +22, 940bp). This confirmed that the major methylated region was the hotspot 
(41.6% to 75.0%, mean) in all the transgenes tested. These data implied that the CG sites in 
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region A are rapidly “seeded” after transfection and thus may function as a methylation 
center (Figure 19).  
Next, we evaluated the influence of upstream sequences on DNA methylation in the 
hotspot. In SW48A/tTS, compared with the control (No-frag), there were no significant 
differences in hotspot methylation for any of the additional upstream fragments, with the 
possible exception of P16DNF which somehow got reduced DNA methylation although this 
was not statistically significant (Figure 19). 
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Figure 17. Unequal GFP silencing speed in flp-in and flp-in/tTS host cells. GFP 
expression was measured by flowcytometry. Several time points from the first month to the 
fifth were selected for each stable clone under long-term culture. For tTS-expressing flp-in 
host cells, clones were cultured in parallel wells either with or without Dox treatment. (A) 
SW48A and HCT116D. (B) SW48A/tTS with Dox (+) and Dox (-). (C) HCT116D/tTS with 
Dox (+) and Dox (-). GFP expression in long-term cultured tTS-containing clones presented 
partial inducibility in response to Dox. Maintaining clones under Dox could not prevent GFP 
silencing in the end, but could slow down the process at least in some HCT116D/tTS clones. 
All of the SW48A/tTS clones were refractory to the inducible GFP expression at the earliest 
detection time. 
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Figure 18. Sensitive CG sites to de novo DNA methylation by bisulfite pyrosequencing. 
(A) The graphical distribution of CG sites in tetO-pINSL6-EGFP. The subcloned 940-bp 
pINSL6 consists of part of the CGI and two short LINE elements. Amplification of bisulfite-
converted DNA covers 5’-end of EGFP to distinguish it from the endogenous pINSL6 (thick 
line). The small characters and arrows refer to the pyrosequencing target sites for regional 
methylation. (B) The regional methylation of CG sites in the control construct (No-frag) 
which does not carry any additional fragment upstream of tetO-pINSL6.   
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Figure 19. Methylation patterns of pINSL6 in SW48A/tTS at the second month. (A) The 
graphical distribution of CG sites in tetO-pINSL6-EGFP. Amplification of bisulfite-
converted DNA covers 5’-end of EGFP to distinguish it from the endogenous pINSL6 (thick 
line). (B) Bisulfite-sequencing results displayed in circles (methylated CG sites as closed 
circles and unmethylated sites as open circles) and (C) calculated in four segments. No-frag, 
for pINSL6 only, and without any fragments from neither RIL nor P16. RILWH, RILUP, 
RILCEN, and RILDN represent transgenes with fragments from the RIL promoter (the entire 
promoter, upstream LINE, central CGI and downsteam regions respectively). P16- prefix 
represents those with fragements from the P16 promoter (UPF and UPR, upstream SINEs in 
forward and reverse orientation; DNF and DNR, downstream Alu in forward and reverse 
direction; DNF3 and DNR3, three tandem downsteam Alus in forward and reverse 
orientation). Thin lines stand for the segments divided based on pyrosequencing and bisulfite 
cloning/sequencing results. The bar graphs in (C) were average methylation levels of the 
subdivisions of bisulfite-sequencing-examined pINSL6 (mean±SEM). Asterisks, statistically 
significant difference in comparison with No-frag (p<0.05). 
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Figure 20. The correlation of two assays in analyzing segmental methylation of pINSL6. 
The Pearson correlation coefficient is calculated for the average methylation levels between 
11 paired bisulfite-sequencing and pyrosequencing results. The 95% confidence interval of 
the best-fitted line is shown in dotted curves. 
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The effects of repetitive elements on DNA methylation spreading 
Another point out of the data in Figure 19 is the possibility that methylation was 
spreading from the hotspot to nearby sequences. We examined the effects of upstream 
sequences on spreading over time. As shown in Figure 19, upstream sequences from either 
the RIL promoter or the P16 promoter did bring up a distinct difference in the methylation of 
region C (the CGI of pINSL6). In the case of RIL, higher methylation was obtained for those 
constructs that included the upstream portion (18.5% for RILWH, p<0.01, t-test; 19.6% for 
RILUP, p<0.01, t-test) which is mostly a LINE element (L2), while the CGI (RILCEN, 
8.9%) or the downstream portion (RILDN, 4.4%) did not affect the methylation significantly 
compared with the control (No-frag). A similarly enhanced methylation could be observed if 
the three upstream SINE elements from the P16 promoter were present in the construct 
(P16UPF, 8.7%, p<0.05; P16UPR, 13.0%, p<0.05). The transitional region between the 
hotspot and the CGI demonstrated intermediate methylation levels with little difference 
between transgenes, although RILUP and P16UPF also showed trends of higher methylation. 
The EGFP CDS achieved a pattern similar to the CGI. The assays of bisulfite 
pyrosequencing and bisulfite cloning-sequencing revealed a good correlation (correlation 
coefficient r was 0.78 for LINE-hotspot, 0.82 for transitional, and 0.88 for CGI) (Figure 20); 
we therefore used bisulfite pyrosequencing for subsequent analysis.  
 
Gradual accumulation of methylated cytosine over time 
The changes in transgene methylation were monitored over time in each single clone 
obtained. In figure 21, the methylation of several representative transgenes (No-frag, 
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RILWH, RILDN, P16UPR and P16DNF) in SW48A/tTS are plotted over four time points 
from the second to the fifth month. Prolonged culture time led to variable increase of 
methylation levels. For instance, the highest increase in hotspot methylation was 32.0% for 
P16UPR, 30.5% for P16DNF and 39.9% for P16UPF. In the CGI, the top changes were 
39.0% for P16UPR and 29.5% for P16UPF. Together with the data from the adjacent 
regions, the transgenes had two distinct patterns. Some became more methylated at all early 
time points and tended to maintain their higher levels with rapid accumulation in most 
regions except the hotspot which was maximally methylated early. The most striking 
acceleration in the CGI were P16UPR and P16UPF (which contain three SINEs) and RILWH 
(which contains an L2 element). For other constructs, methylation was maintained with a 
slow and gradual increase in levels similar to the control. Examples of this pattern included 
RILDN and P16DNF. 
 
Long-distance spreading was not direction-dependent 
Given that the CGI of pINSL6 could become more methylated with repetitive 
elements present upstream, we wondered if regions further upstream or downstream would 
display a similar trend. We measured methylation levels of the distal LINE (5’LINE), the 
tetO element, and the fragments (336bp to 1485bp) (Figure 21), as well as the reporter EGFP 
(720bp) and the selection marker hygromycin B (4565bp upstream to the start of fragments) 
(Figure 22) in SW48A/tTS at the fifth month. Methylation was found expanded into a region 
up to 6kb away from “hotspot” and those with repetitive elements upstream were subjected to 
more methylation, which confirmed the effect of repetitive elements on methylation 
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spreading.  Since EGFP and hygromycin B are located in two directions from TSS, spreading 
apparently was not dependent on the direction.  
 
Promoted CGI methylation arose from adjacent de novo methylation 
According to the “seed and spread model”, methylation spreading leads to CGI 
methylation once the protective boundaries are broken-down (63, 64). However, inherent cis-
signals for initiating DNA methylation within CGIs independent of a hotspot might be an 
alternative mechanism that does not require spreading. To address this possibility, we 
separately constructed a truncated pINSL6 (tr-pINSL6) by removing all the sequences 
upstream of the CGI including both LINE elements. In the same SW48A/tTS host cell, 
transgenes (No-frag, RILWH and P16UPF) without the methylation hotspot (tr-pINSL6) 
achieved prominently lower CGI methylation at the second month (3.4% vs 7.5% for No-
frag, 8.0% vs 23.5% for RILWH and 7.1% vs 12.9% for P16UPF The difference was even 
more pronounced at 3 months: the truncated pINSL6 did not elevate CGI methylation from 
the second to third month, in contrast to the methylation increase by an average of 10% in the 
LINE-containing pINSL6 (Figure 23). GFP was silenced to the same level in all the 
constructs. We conclude that the CGI methylation arose more easily from spreading instead 
of de novo events. Nevertheless, the CGI itself was not absolutely methylation-free 
indicating DNMTs may target randomly independent of methylation centers but in a less 
efficient way (Figure 21). 
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Figure 21. Gradual accumulation of transgene methylation in SW48A/tTS over time, 
sampled at 2, 3, 4 and 5 months. Also refer to the Figure  for methylation in HCT116D/tTS 
and HCT116D. Trend lines represent fragments subcloned to the upstream of tetO-pINSL6. 
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Figure 22.  Methylation of two regions furthest away from pINSL6 which are inside of 
EGFP and hygromycin B. Methylation levels of four distinct transgenes in SW48A/tTS at 
the fifth month are shown here. Bars, average methylation levels (mean±SEM). Asterisks, 
significant difference in comparison to No-frag (p < 0.05). 
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A highly repressive environment can enhance de novo methylation and methylation 
spreading 
Methylation results from SW48A/tTS, the most repressive condition have been 
discussed so far, and we next investigated the influence of tTS by comparison of the patterns 
in SW48A/tTS and SW48A. It could be seen that the repetitive elements were not the only 
factor in promoting methylation spreading, the presence of tTS enhanced both de novo 
methylation in “hotspot” and methylation spreading into the CGI and distal areas. First, the 
hotspot in SW48A only achieved 13.1% to 35.8% methylation at the second month and by 
the fifth month the methylation rose to no more than 50% (26.1% to 49.1%) (Figure 24); in 
contrast, SW48A/tTS host cells already induced 23.3% to 73.6% methylation at the second 
month and by the fifth month 42.0% to 84.2%.  
A validation experiment was carried out by removing tetO (notetO-pINSL6) from the 
transgenes (No-frag and RILUP). In SW48A/tTS at the second month, the hotspot of notetO-
pINSL6 obtained methylation levels very close to those of pINSL6 in SW48A host cells 
(15.6% for No-frag and 23.0% for RILUP) (Figure 25). The same trend was maintained at 
the third month. Removal of the tetO allowed GFP expression to be 74% for No-frag and 
65% for RILUP on average, ruling out possible systemic interferences caused by cell 
engineering, such as non-specific effects due to tTS insertion in the course of generating 
SW48A/tTS host cells. 
Furthermore, in the absence of tTS, the CGI methylation presented much lower levels 
and little variation in different constructs (5.0% to 16.1% at the fifth month), which was in 
vast contrast to the patterns shown in SW48A/tTS (Figure 24). The loss of influence from 
repetitive elements was observed in the other adjacent regions including transitional, 5’-
LINE, tetO and the fragments. As well, methylation accumulated in a slower rate over time 
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(Figure 26). This suggests that the effect of repetitive elements on methylation spreading is 
limited by the extent of local repression, and both repetitive elements and strong repression 
are required for a CGI to become significantly methylated. 
 
Local heterochromatin in transgenes 
ChIP analysis was performed to study local enrichment in repressive histone marks. 
The active marks (H3K4me3 and H3K9ac) and the inactive marks (H3K9me3 and 
H3K27me3) were analyzed in the cells sampled from the second and sixth month. The assays 
for the quantitative real-time PCR were designed at the connection region of tetO-to-pINSL6 
and pINSL6-to-EGFP respectively to distinguish the exogenous from the endogenous 
pINSL6. Compared with the control regions (GAPDH and RARB), the pINSL6 in transgenes 
was enriched for H3K9me3 (two to three-fold more than GAPDH and RARB), and devoid of 
H3K4me3 and H3K9ac, indicating a local repressive environment. By contrast, H3K27me3 
was not enriched in pINSL6, therefore the repression was more related to recruitment of 
H3K9me3 (Figure 27). However, there were neither differences of inactive (H3K9me3 and 
H3K27me3) histone marks between SW48A/tTS and SW48A, nor the differences between 
the repetitive-elements-containing transgene (RILUP) and pINSL6 only (No-frag). Thus, at 
late time points examined, the enrichment for repressive marks had already reached a stable 
level.  
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Figure 23. Comparison of transgene behaviors between the truncated and complete 
pINSL6 in SW48A/tTS. (A) The truncated pINSL6 (tr-pINSL6). (B) CGI methylation (the 
second and third month). (C) GFP expression (the second month). Refer to Figure 17 for 
more GFP expression profiles.  
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Figure 24. Methylation profiles of pINSL6 in flp-in host cells by pyrosequencing. 
Regional methylation detected in each transgene from SW48A/tTS and SW48A at the fifth 
month. 
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Figure 25. Comparison of CGI methylation and GFP expression between tetO (-)-
pINSL6 in SW48A/tTS, tetO(+)-pINSL6 in SW48A and tetO(+)-pINSL6 in SW48A/tTS. 
(A) Pyrosequencing was performed for clones at the second and third month after 
transfection. (B) Flow cytometry was used to detect GFP expression at the second month. 
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Figure 26. Regional methylation of transgenes in SW48A at the second month by 
pyrosequencing. Bars, average methylation levels (mean±SEM). Statistical analysis did not 
show significant of any fragment compared with control construct (No-frag). 
  
N
o-
fr
ag
R
IL
W
H
R
IL
U
P
R
IL
C
EN
R
IL
D
N
P1
6U
PF
P1
6U
PR
P1
6D
N
F
P1
6D
N
R
P1
6D
N
F3
P1
6D
N
R
3
N
o-
fr
ag
R
IL
W
H
R
IL
U
P
R
IL
C
EN
R
IL
D
N
P1
6U
PF
P1
6U
PR
P1
6D
N
F
P1
6D
N
R
P1
6D
N
F3
P1
6D
N
R
3
N
o-
fr
ag
R
IL
W
H
R
IL
U
P
R
IL
C
EN
R
IL
D
N
P1
6U
PF
P1
6U
PR
P1
6D
N
F
P1
6D
N
R
P1
6D
N
F3
P1
6D
N
R
3
0
10
20
30
40
50 Hotspot CGITransitional
M
et
hy
la
tio
n%
N
o-
fr
ag
R
IL
W
H
R
IL
U
P
R
IL
C
EN
R
IL
D
N
P1
6U
PF
P1
6U
PR
P1
6D
N
F
P1
6D
N
R
P1
6D
N
F3
P1
6D
N
R
3
N
o-
fr
ag
R
IL
W
H
R
IL
U
P
R
IL
C
EN
R
IL
D
N
P1
6U
PF
P1
6U
PR
P1
6D
N
F
P1
6D
N
R
P1
6D
N
F3
P1
6D
N
R
3
N
o-
fr
ag
R
IL
W
H
R
IL
U
P
R
IL
C
EN
R
IL
D
N
P1
6U
PF
P1
6U
PR
P1
6D
N
F
P1
6D
N
R
P1
6D
N
F3
P1
6D
N
R
3
0
10
20
30
40
50 5'-LINE FragmenttetO
M
et
hy
la
tio
n%
97 
 
The presence of tTS made trasgenes refractory to TSA-induced derepression 
We also tried to confirm the stronger repression related to the presence of tTS by 
treating clones of RILWH and No-frag from SW48A and SW48A/tTS at the fourth month. 
Compared with the control group, the DNA methylation inhibitor 5-aza-2’-deoxycytidine 
(DAC) induced global LINE-1 demethylation by 20% to 30% as well as local “hotspot” 
demethylation by 5% to 18%, but did not reactivate GFP expression. The HDAC inhibitor, 
TSA induced GFP re-expression without any demethylation. GFP expression was 
significantly restored by TSA for the clones from SW48A, but was not affected in 
SW48A/tTS, confirming the function of tTS in enforcing local repression (Figure 28). 
 
The effects of cell lines or genomic loci on DNA methylation recruitment 
Besides the host cells from SW48, we utilized a different cell line HCT116 with a 
different integration site (HCT116D) to assess the conservation of DNA methylation in 
response to transcriptional repression. In both HCT116D and HCT116D/tTS, de novo 
methylation behaved in the same way as in SW48A whereby the hotspot achieved quicker 
and higher methylation than the other regions (Figure 29). However, methylation spreading 
was slower, not distinctively affected by the upstream repetitive elements, and was short of 
correlation with the presence of tTS in HCT116D/tTS. Thus, DNA methylation of the 
hotspot appeared to be an intrinsic property of the CG sites, whereas methylation spreading 
was greatly influenced by cell line context and/or integration sites. 
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Figure 27. ChIP-qPCR for analyzing the enrichment of histone marks in pINSL6. 
Antibodies against active marks (H3K4me3 and H3K9ac) and repressive marks (H3K9me3 
and H3K27me3) were used to pull down sonicated chromatin. All the values were 
normalized to H3 and H3 occupancy was calculated as the percentage of input. ACTB and 
GAPDH as the control regions for active marks; RARB as the positive control for 
H3K27me3. TETO-INSL6 and INSL6-GFP are designed at the 5’-end and 3’-end of pINSL6 
to distinguish it from the endogenous one. (A) Transgenes with no fragment or RILUP in 
SW48A and SW48A/tTS at the second month. (B) Transgenes with no fragment in SW48A 
and SW48A/tTS at the sixth month. 
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Figure 28. The reaction of SW48A and SW48A/tTS clones to epigenetic drug treatment. 
The cells (transgenes with No-frag and RILWH) of the fourth month were treated with DAC 
(200nM) for four days and/or TSA (800nM) during the last day and controls were cultured in 
regular media. (A) Global DNA methylation (LINE-1) and local methylation of the identified 
methylation hotspot in pINSL6 were measured and compared with the respective control 
group. (B) GFP expression was detected by flowcytometry. All the values were averaged 
from biological duplicates.  
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Figure 29. Methylation profiles of pINSL6 of transgenes in flp-in host cells. 
Pyrosequencing was used to detect regional methylation patterns as described before. (A) 
Methylation in HCT116D/tTS and HCT116D, sampled at the fifth month. The x-axes 
represent fragments subcloned upstream of tetO-pINSL6. Bars, average methylation levels 
(mean±SEM). (B) Gradual accumulation of transgene methylation.Three time points from 
the first to the fifth month are shown for HCT116D/tTS and HCT116D. 
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Discussion 
Our investigation of de novo methylation and spreading process was realized through 
a site-specific integration system with enforced local transcriptional repression. By studying 
expression, DNA methylation and histone modifications of transgenes at a single integration 
site, we were able to distinguish several aspects involved in DNA methylation of promoter-
CGIs. We find that (1) DNA methylation originates from certain CG sites within a LINE 
element; (2) methylation spreading into a promoter-CGI is facilitated by transcriptional 
repression, presence of additional repetitive elements and is site-specific; (3) transcriptional 
repression is required but not sufficient to promote DNA methylation.  
Repetitive elements (REs) comprise ~45% of human genome, most of which are 
derived from the activity of transposable elements (123). They are considered to account for 
global DNA methylation in normal somatic cells, while become hypomethylated in cancers 
increasing the risk of genomic instability (2). In mammals, almost 25% of the analyzed 
promoter regions contain repetitive DNA (124) and not all of them are deficient of 
methylation in cancer cells, such as SINE sequences located upstream of the P16INK2A 
promoter (125) and the LINE elements at the upstream of RIL promoter (109). So we 
evaluated the roles of CGI-promoter-adjacent repetitive elements in DNA methylation 
recruitment and spreading. The first observation of our experiments is “seeding” of DNA 
methylation in transgenes. The exogenous 940bp INSL6 promoter consists of two short 
LINEs (L2, divergence 27.3%, RepeatMasker; L4, 20.0%) upstream of a CGI. There are six 
CGs across the repeat region, but only the proximal two CGs of the L2 with the next CG site 
achieved distinguished methylation from the adjacent areas at the earliest time point in 
almost all the constructs examined. The methylation was induced independently of cell lines 
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(HCT116 and SW48), genomic loci or the strength of transcriptional repression, while the 
extent of methylation was elevated by the presence of tTS and affected by cell line and/or 
loci used. Therefore, repetitive elements could serve as cis-signals for de novo DNA 
methylation in cancer cells, nonetheless, not all the CGs but a few could be involved. 
However, since only the INSL6 promoter was analyzed in the system, we do not know if 
there are any common sequences assigned by DNMTs which may be elucidated by genome-
wide analysis. Also, the “seeding” event may be determined by dynamic nucleosome 
deposition as suggested by de novo methylation of the P16INK4A CGI in post-selection 
primary human mammary epithelial cells (HMECs) (84).     
The second function of repetitive elements located further upstream is to cis-regulate 
methylation spreading into the adjacent regions from de novo sites, especially into CGIs. The 
LINE element (L2, divergence 26.9%) from RIL promoter and three concatenated upstream 
SINEs (MIR, divergence 24.1%; Alu, 8.7%; Alu, 9.0%) from P16 promoted striking 
methylation of the CGI in SW48A/tTS which represents a genomic locus with strengthened 
silencing in a cancer cell. In other host cells, spreading was not significant if there was any, 
so these REs we studied here may not be so strong as to overcome the protective machinery 
independently of the repressive strength, or alternatively, repetitive elements have to 
cooperate with transcriptional repression in order to render methylation spreading. 
Importantly, not all REs contribute to methylation spreading as the downstream Alu of P16 
(divergence 11.9%) did not make the adjacent methylation get to the same level as the 
upstream REs did. Previously, some repetitive elements are empirically defined as cis-
regulatory elements (124) and genome-wide analyses have shown some human and mouse 
promoters are derivates from specific repetitive elements (126). Thus, the LINE of RIL or 
104 
 
SINEs of P16 may work as another kind of cis-signal to recruit either stronger transcription 
repressor or more chromatin remodeling factors thereby facilitate the access of DNMTs to 
the CGI.  
The organization of REs may influence methylation spreading. Increased transgene 
copies was reported to induce more methylation and more compacted chromatin in mouse 
lines (127), and imprinted genes more frequently contain tandem repeat arrays in their CpG 
islands than randomly selected genes in both mouse and human (128). We also observed that 
three upstream SINEs of P16 were more effective than one Alu from the downstream in 
spreading, and three tandem downstream Alus seemed also to have a bit more impact. 
Presumably, although the compaction caused by one copy of RE may be insufficient, adding 
up the effects of several copies could possibly get over the threshold and make more DNMTs 
accessible to the adjacent regions. But this hypothesis still needs further examination. 
One strategy of our experiments was to control the local repression strength by using 
the tetracycline-controlled transcription silencer (tTS). The tTS is usually used in inducible 
expression system, and here we are employing its role in sequential recruitment of the H3K9-
specific histone methyltransferase (e.g. SETDB1), HP1, and the histone deacetylase 
(HDAC)-containing complex via KRAB-KAP1 cooperation (117, 118). Hence, even over a 
range of euchromatin, a highly compact heterochromatin patch can be generated and 
maintained for quite a few generations. On the other hand, pINSL6 is not a strong promoter 
because GFP was gradually silenced and the promoter was enriched for repressive histones 
(H3K9me3) probably through adopting the endogenous regulators targeted at pINSL6. 
Therefore, pINSL6 could set up a repressive background, and usage of tTS increased the 
repression to a higher and long-standing level. The stronger the localized repressive 
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heterochromatin was, the faster de novo methylation occurred and the more chance the CGI 
could become methylated.   
The variation of position effect was another trans-regulatory aspect taken into account 
as well. Only tTS could not guarantee the heterochromatin patch inserted with transgenes to 
reach as high as the level permissive for DNA methylation. Gene body methylation in 
mammals has been confirmed in many studies (129). As the integration sites of the host cells 
are located intragenically, it is acceptable that they were densely methylated and lacked 
enrichment for active histone marks (H3K4me3 and H3K9ac). However, although tTS was 
expressed and functional in both cells (SW48A/tTS and HCT116D/tTS), the one in 
HCT116D/tTS served almost nothing for methylation spreading. This brings up the question, 
to what extent transgene methylation is subjected by a position or a large domain centered 
over the position, which needs detailed investigation in the future.   
Finally, the disconnection of histone modifications and DNA methylation in the CGI-
promoter was further revealed from several aspects. The first one is non-appearance of 
methylation spreading in host cells except SW48A/tTS while reporter expression was 
gradually suppressed and the promoter was highly enriched with H3K9me3. Second, 
methylation was hardly recruited into the CGI of the truncated pINSL6 devoid of the LINE 
element even in SW48A/tTS. Moreover, treatment with DAC only was not able to recover 
GFP expression along with DNA demethylation. Among the set of factors recruited by tTS 
binding, HP1 and the H3K9-specific HMT (e.g. SETDB1) have been shown interplayed with 
DNMTs (127), and the above findings confirmed DNA methylation as the consequential 
event of transcriptional silencing, but they also indicated transcription is more closely related 
to chromatin conformation and DNA methylation may be an event reflecting relatively 
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stronger local suppression. The disconnection of histone modifications and DNA 
methylation, therefore, could provide the flexibility for dynamic epigenetic machinery in 
regulating gene transcription. 
To summarize, by controlling variable elements in a site-specific integration system, 
we investigated several aspects involved in triggering DNA methylation: (1) repetitive 
elements adjacent to CGI-promoters that are frequently hypermethylated in cancer cells; (2) 
the extent of transcriptional repression in regulating DNA methylation; (3) the effect of 
genomic position/cell line on DNA methylation. We were able to demonstrate all of them 
could influence methylation patterns around a CGI-promoter so as to confer flexibility in 
epigenetically regulating gene silencing under various circumstances.  
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Chapter 5 
Introduction of DNMT3B lead to partially recovered methylation patterns 
Introduction 
In the previous sections, we utilized transgenes to investigate cis- and trans-regulation 
in de novo DNA methylation and spreading. Because integration sites were kept consistent, 
the comparison is more reliable than random integration. However, we still did not define 
what kinds of sites/sequences/motifs are favored by different DNMTs. In order to answer this 
question, we used a well-defined colorectal cancer cell with double disruption of DNMT1 
and DNMT3B as another model system, and re-expressed DNMT3B or DNMT1. A newly 
developed method, DREAM, was employed to search for re-methylated CG sites, aided by 
bioinformatic tools.  
HCT116 DKO (DNMT1-/- DNMT3b-/-) was generated by serial homologous 
recombinations and does not keep the methylation patterns in HCT116, because about 95% 
of genomic methylation is lost (8, 9). Interestingly, the P16INK4A promoter could gradually 
regain methylation if culture time was prolonged to over 80 passages. Although this is likely 
due to remnant activity of DNMT3A and alternatively spliced DNMT1, remethylation 
suggested signals for DNA methylation have not been lost. Hence, this genetically 
engineered cell line could serve as a model to assess the preference of DNMT3B or DNMT1 
in remethylation, so as to shed light on the machinery of de novo methylation in cancer cells.  
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Results 
Methylation is not equally recovered in DKO cells 
HCT116 DKO (DNMT1-/- DNMT3B-/-) was generated through serial homologous 
recombinations to disrupt methylation machinery in the colorectal cancer cell HCT116. Both 
genes were knocked down in part of their genomic sequences. DNMT1 was targeted at exon 
3-5, so that global methylated cytosine was reduced by ~20% and enzyme activity was 
reduced by ~93%. Gene-specific methylation was not equal in DNMT1-/-. For instance, a 
single-copy gene, p16INK4A was still methylated ~50%, and TIMP-3 was still fully 
methylated and silenced (130). For DNMT3B, exon 2-21 was replaced to remove active site 
critical to catalysis, therefore DKO cells lost ~95% methylated cytosine and almost all 
enzyme activity (9). The gene-specific methylation was also suffered, as shown by a set of 
genes identified to have increased expression in DKO due to loss of methylation through 
microarray screening in HCT116 and DKO (131). However, the deletion of DNMT1 was not 
complete, and there was alternatively spliced transcript detectable with catalytic domains 
(132). Further fully disruption of the exons necessary for active DNMT1 in HCT116 resulted 
in hemimethylation of ~20% of CG-CG dyads and caused G2 arrest and cell death (133). 
Due to the remaining activity of incompletely disrupted DNMT1 and DNMT3A, DKO cells 
exhibited partially recovered methylation and growth rate at passage 87 (93), although it 
became significant  at least from passage 50. 
Before stable re-expression of DNMT3B or DNMT1, we assessed methylation status 
of the DKO clones (passage 35 to passage 40) to define a starting level for our experiments. 
Assays for pyrosequencing were used not only for gene-specific methylation but also for 
global methylation. In contrast to heavy methylation of over 80%, the CGIs of SFRP1, 
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SFRP2, SFRP4, SFRP5 and RIL were almost methylation-free. The single-copy gene, 
p16INK4A had its CGI re-methylated to the same level of ~50% as in parental HCT116 
cells, except for one region (named as p16-4-1ADD) that was not fully restored (~20%). We 
also examined mixed populations of DKO transfected with DNMT3B1 or DNMT1b, and 
observed similar results as in DKO cells. LINE-1 methylation could represent global DNA 
methylation levels. We picked 13 single clones (passage 48) of DKO cells and their 
methylation levels were somewhere between passage 45 and passage 50, but there were 
variations in clonal status (Figure 30). This suggested the heterogeneous conditions of single 
DKO cells in DNA methylation. 
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Figure 30. Methylation is not equally recovered in DKO cells. Pyrosequencing to examine 
average methylation levels at several CGI-promoter regions. HCT116, wild type; DKO36 
and DKO40, DKO cells of passage36 and passage40; DKO/6.3B-40, DKO/3.1-40, DKO/6-
40 and DKO/3-39 are mixed DKO clones transfected with pcDNA6V5His/DNMT3B, 
pCDNA3.1HA/DNMT1, pcDNA6V5His, and pcDNA3.1HA; SSSI HCT116, methylase sssI-
treated HCT116 genomic DNA. (A) DNA methylation in the promoter-CGI of p16INK4A, 
SFRP1, SFRP2, SFRP4, SFRP5, and RIL. (B) Clonal variation of LINE-1 methylation in 
DKO (passage 48). 
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Figure 31. Re-expression of DNMT3B1 in DKO cells moderately recovered global DNA 
methylation. (A) Quantitative RT-PCR to screen out stable single clones with positive 
expression of DNMT3B1. Two Taqman assays were designed to cover the deleted exons and 
junction of DNMT3B-to-V5His in the transcript. Ct values were normalized to GAPDH. (B) 
Western blot to test the expression at the protein level. (C) Pyrosequencing to single clones 
with partial re-methylation of LINE-1. Gene-specific methylation was shown for the CGIs of 
RIL, SFRP1, SFRP2, SFRP4 and SFRP5. (D) Pyrosequencing results of LINE-1 in single 
clones from passage 40 to passage 50.  
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Figure 32. Re-expression of DNMT1b in DKO cells moderately recovered global DNA 
methylation. (A) Quantitative RT-PCR to screen out stable single clones with positive 
expression of DNMT1b. Two Taqman assays were designed to cover the deleted exons and 
junction of HA-to-DNMT1b in the transcript. Ct values were normalized to GAPDH. (B) 
Pyrosequencing results of LINE-1 methylation in single clones from passage 40 to passage 
50.  
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Re-expression of DNMT3B or DNMT1 moderately recovered global DNA methylation 
DKO cells (passage 36 or 37) were transfected with pCDNA6V5His/DNMT3B1 
(blasticidin) or pCDNA3.1HA/DNMT1B (zeocin). The stable single clones were selected 
under blasticidin or zeocin respectively. The expression was examined by RT-PCR and 
western blotting. Besides single clones with detectable expression of DNMT3B or DNMT1, 
we had to select which clones regain global methylation or/and gene-specific methylation. 
Pyrosequencing results showed in Figure 31 and Figure 32 described most of the picked 
single clones did not have elevation in their methylation levels compared with the same 
passage number of DKO cells, and there were only two clones, 3B-7 and 3B-12, whose 
LINE-1 methylation increased by ~18% and ~16% (passage 40) while none of examined 
gene-specific methylation had any changes (RIL, SFRP1, SFRP2, SFRP4 and SFRP5). There 
is no need to test p16 methylation since it has already recovered methylation. As for 
transfection of DNMT1, two clones (3.1-25 and 3.1-45) regained LINE-1 methylation of 
5%~6% (passage 45) which was not much compared with DNMT3b re-expression.  
 
Preferential representation of CGI methylation for DREAM 
We first sequenced DREAM libraries (part A and B) prepared from HCT116, DKO 
(passage 36), 3B-7 and 3B-12 (passage 52). The experiments for validation before 
sequencing are shown in Figure 33. The size of each library was checked on 2% agarose gel 
and effective removal of primer dimers was validated on Bioanalyzer (Agilent) by the 
sequencing core facility (M.D. Anderson Cancer Center). Pyrosequencing results 
demonstrated good correlation between theoretical and actual methylation levels of spiked 
DNAs. TA-cloning/sequencing of libraries also indicated good quality of each library, for 
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instance, out of 20 effective CCCGGG sites (from 10 correct TA-clones) for HCT116 part B 
(HCT116-B), there were 11 XmaI (CCC) sites and 9 SmaI (GGG) sites, whereby methylation 
percentage was 55%; for DKO-A and DKO-B, 0% and 13.6%, which were within the 
expectation range. 
Here, DREAM libraries were sequenced on GAII pipeline and pre-analyzed by 
bioinformatic tools commercially available (ELAND) and specifically designed for DREAM 
in Department of Bioinformatics and Computational Biology (Dr.Shoudan Liang). Overview 
of the results is listed in Figure 34. Coverage of SmaI sites for each sample includes both part 
A and part B. Excluding tags from spiked DNA, the average methylation levels of HCT116, 
DKO, 3B-7 and 3B-12 were 44.0%, 5.2%, 22.8% and 17.6%, which were consistent with 
expected differences. Apparently, re-expression of DNMT3B induced moderate re-
methylation in DKO cells.  
Because DREAM utilizes restriction enzyme-based digestion, the resolution is merely 
restricted to regions with SmaI/XmaI sites (CCCGGG), which appear once out of every 4096 
bases theoretically. Genomic distribution of this site has its own preference. Namely, the 
entire human genome has 378855 SmaI sites (Hg18) (220 with no specific location 
information on a “random” chromosome), out of which only 11.76% are in CGI (44349 sites) 
and 61.81% are in various repeats (234182 sites) (Figure 35). Whereas, the sites obtained 
from sequencing all of four samples (HCT116, DKO, 3B-7 and 3B-12) were counted by 
selecting those with ≥ 5 tags, which covered 20.79% (78762 sites) of genomic SmaI sites. If 
taking the properties of location into account, we found that 66.65% (29557 sites) of genomic 
CGI-SmaI sites (44349 sites) and 14.71% (49205 sites) of genomic nonCGI-SmaI sites 
(334506 sites) were represented by DREAM; as for location in repeats, 4.68% (10963 sites) 
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of genomic repeats-SmaI sites (234182 sites) and 46.86% (67799 sites) of genomic non-
repeats-SmaI sites (144673 sites) were obtained. These series of numbers suggested that 
DREAM, as restriction enzyme-based technology, is more likely to reflect methylation of 
SmaI sites in CGIs and has lost much information of those in repeats. 
 
Re-expressed DNMT3B favored non-CGIs 
Re-introduction of DNMT3B into DKO cells induced moderate regain methylation in 
selective SmaI sites. Here, we took the common set of SmaI sites covered in all four libraries 
(HCT116, DKO, 3B-7 and 3B-12) and every site has more than 5 tags sequenced (≥ 5 tags). 
The scatter plots in Figure 36A display methylation levels in HCT116, 3B-7 and 3B-12 
versus DKO. We aimed to identify sites which were greatly demethylated in DKO cells and 
then obtained significant increase in 3B-7 and 3B-12. Therefore, we first applied Fisher’s 
exact test (two-tailed) to comparisons between HCT116 and DKO, 3B-7 and DKO, and 3B-
12 and DKO as to methylated and unmethylated tag numbers. The p-value was adjusted by 
Benjamini-Hochberg method and sites with adjusted p-value (q-value) <0.05 were assigned 
to the set with significant difference in DNA methylation. Thus, 52579 sites for HCT116 
versus DKO, 30766 sites for 3B-7 versus DKO, and 26249 sites for 3B-12 versus DKO had 
significantly different methylation levels. The number for the common set of significantly 
different sites was 21793, which was 27.67% of the total common set. If location properties 
considered, the percentage of CGI-SmaI sites in the significant set (12.20%) was less than 
that of non-CGI-SmaI sites (36.96%), while there was similar percentages of repeat-SmaI 
sites (24.75%) to non-repeat-SmaI sites (28.14%). Figure 36B shows the general levels of 
sites with significant difference in the above two-two comparisons. 
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However, when definition of “methylated” and “unmethylated required, a second 
criterium was applied using 20% as the cut-off for methylation levels. Among the set of sites 
whose methylation became significantly different in DKO (p < 0.05 in HCT116 vs. DKO), 
the portion of remethylated ones (p < 0.05 for all, methylation ≥ 20% in HCT116, 3B-7 and 
3B-12, and methylation < 20% in DKO) were found less in CGI-SmaI-sites (13.15%) than in 
non-CGI-SmaI sites (26.44%). Consistently, the portion of un-remethylated one (p <0.05 for 
HCT116 vs. DKO, p >0.05 for both 3B-7 vs. DKO and 3B-12 vs. DKO, methylation ≥ 20% 
in HCT116 and methylation < 20% in DKO, 3B-7 and 3B-12) were more likely in CGI-SmaI 
sites (42.52%) than non-CGI-SmaI sites (13.84%) (Figure 36). This suggested CGIs were 
less sensitive to DNMT3B due to unclear mechanisms. 
 
Promoters were more resistant to re-expressed DNMT3B  
We took the above significantly remethylated and un-remethylated groups of SmaI 
sites, and analyzed their locations to find out the regions which were resistant to DNMT3B. 
The percentage of SmaI sites for each sliding window of 500bp was calculated in regard to 
the location property, and lines were plotted with relative distance to the closed transcription 
start site (TSS) for each percentage (Figure 37). As shown before, more CGI-SmaI sites were 
prone to be un-remethylated. A further finding was also as expected that promoters were 
more resistant for remethylation.  
We listed the genes that have CGI-promoters and whose CGI-promoters achieved 
significant remethylation on at least one SmaI sites (Table 8). The promoter was defined as 
regions TSS-2000bp to TSS+500bp and the CGI-promoter has its TSS inside a CGI. 
Examples are also shown in Figure 39.  
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A 
 
B 
 
Library No. SmaI No. XmaI Sites/clones sent
HCT116‐A 5 13 18/9 12
HCT116‐B 9 11 20/10 12
DKO‐A 22 0 22/11 12
DKO‐B 19 3 22/11 12
TA-seq
Pyro-seq: spiked DNA
LA L306 LucG EGFP T353 T324
0% 22% 22% 50% 70% 100%
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Figure 33. Preparation of DREAM libraries. (A) Pictures of prepared libraries after size 
selection (200bp ~ 500bp). Part A and B are equal slices from the same gDNA. (B) 
Validations of prepared libraries by pyrosequencing of spiked DNAs and TA-
cloning/sequencing.   
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HCT116
Avg.Met% 44.00
no. SmaI sites 151,638
reference SmaI sites 7
total sites covered 151,645
total tag number 40,629,732
total reference tags 2,287,296
no. sites (exclude ref.) total tags
sites(>0tag) 151,638 38,342,436
sites (>=5tags) 118,422 38,266,227
sites(>=10tags) 96,768 38,119,632
sites(>=20tags) 75,259 37,822,520
DKO
Avg.Met% 5.20
no. SmaI sites 140,330
reference SmaI sites 7
total sites covered 140,337
total tag number 35,977,471
total reference tags 1,826,673
no. sites (exclude ref.) total tags
sites(>0tag) 140,330 34,150,798
sites (>=5tags) 82,841 34,019,190
sites(>=10tags) 58,428 33,862,611
sites(>=20tags) 51,641 33,776,346
3B.7
Avg.Met% 22.81
no. SmaI sites 162,895
reference SmaI sites 7
total sites covered 162,902
total tag number 53,956,332
total reference tags 3,393,334
no. sites (exclude ref.) total tags
sites(>0tag) 162,895 50,562,998
sites (>=5tags) 145,528 50,520,152
sites(>=10tags) 126,320 50,387,957
sites(>=20tags) 102,815 50,058,143
3B.12
Avg.Met% 17.66
no. SmaI sites 164,679
reference SmaI sites 7
total sites covered 164,686
total tag number 52,422,055
total reference tags 2,680,276
no. sites (exclude ref.) total tags
sites(>0tag) 164,679 49,741,779
sites (>=5tags) 153,789 49,713,419
sites(>=10tags) 135,166 49,581,363
sites(>=20tags) 103,135 49,130,066
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Figure 34. Overview of DREAM sequencing results. Libraries prepared from HCT116, 
DKO, and two single clones of DKO/DNMT3B (3B-7 and 3B-12) were sequenced by GAII 
(Illumina). Every table shows combined sequencing results from part A and B which were 
sequenced separately. Average methylation percentage was calculated as (total methylated 
tags) / (total unmethylated tags + total methylated tags), and all these tag numbers did not 
count in those from spiked DNA. Covered numbers of SmaI/XmaI site (CCCGGG) and 
corresponding tag numbers were also counted based on different cut-offs as to each 
SmaI/XmaI site. 
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Figure 35. Technical preferences of DREAM. (A) Absolute numbers of SmaI/XmaI site in 
theoretical human genome (Hg18) and those obtained in all the sequenced libraries of 
HCT117, DKO, 3B-7 and 3B-12 (sites with ≥5 tags). Depending on the properties of 
SmaI/XmaI sites, total numbers are also shown either for in CGI vs. non-CGI or for in repeat 
vs. non-repeat. (B) Percentage of covered SmaI/XmaI sites as relative to genomic sites. 
Results are also listed according to their location properties. 
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Figure 35. Scatter plots for methylation distribution of SmaI/XmaI (CCCGGG) sites. 
(A) The common set of SmaI sites obtained from all four libraries. Only sites with ≥ 5 tags 
were taken into account. HCT116, 3B-7 and 3B-12 are plotted versus DKO. Green dots or 
red dots stand for CGI-SmaI sites, and blue dots for non-CGI-SmaI sites. (B) SmaI sites with 
significant difference in DNA methylation (p < 0.05, adjusted, Benjamini and Hochberg 
method) between two-two comparison of  HCT116, 3B-7 and 3B-12 are plotted versus DKO. 
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Figure 36. CGIs were not sensitive to re-expressed DNMT3B in DKO. (A) Heat map to 
show the methylation ranges of SmaI sites among those whose methylatio was significantly 
different in DKO cells. Sites were classified into non-CGI-SmaI sites (read bar) and CGI-
SmaI sites (green bar). Methylation levels are indicated with colors from 0% to 100%. The 
sets of interest are also pointed out, which are sites remethylated and un-remethylated in 3B-
7 and 3B-12. (B) Calculation of the percentages of each categories with respect to location 
and changes.  
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Figure 37. Percentages of SmaI sites remethylated (top) and un-remethylated (bottom) 
in respect to their distance to the closest transcription start sites (TSS). CGI- and non-
CGI- SmaI sites are plotted for each case. Both p-value < 0.05 and methylation level (20%) 
were considered to calculate the percentages. 
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Figure 38. Examples of remethylation and un-remethylation of CGIs in CGI-promoters. 
Two genes (GUCY2D and LIG1) are shown here. Promoter is the region of TSS-2000bp to 
TSS+500bp; CGI-promoters have the TSS inside the CGIs. 
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Table 8. A list of genes with significant remethylation on at least one SmaI site of CGI-
promoters. 
RefSeq_GeneA Name_GeneA   RefSeq_GeneA Name_GeneA   RefSeq_GeneA Name_GeneA 
NM_000093 COL5A1   NM_004794 RAB33A   NM_032451 SPIRE2 
NM_000180 GUCY2D   NM_005028 PIP4K2A   NM_032638 GATA2 
NM_000234 LIG1   NM_005048 PTH2R   NM_054020 CATSPER2 
NM_000475 NR0B1   NM_005052 RAC3   NM_058197 CDKN2A 
NM_000660 TGFB1   NM_005398 PPP1R3C   NM_080823 SRMS 
NM_000697 ALOX12   NM_005519 HMX2   NM_133261 GIPC3 
NM_000799 EPO   NM_005586 MDFI   NM_133457 EMID2 
NM_000843 GRM6   NM_005662 VDAC3   NM_138437 GPRASP2 
NM_000863 HTR1B   NM_005961 MUC6   NM_138632 TRIOBP 
NM_000961 PTGIS   NM_006262 PRPH   NM_138689 PPP1R14B 
NM_001001852 PIM3   NM_006315 PCGF3   NM_138769 RHOT2 
NM_001002034 FAM109B   NM_006794 GPR75   NM_145004 ADAM32 
NM_001003841 SLC6A19   NM_006936 SUMO3   NM_145282 LOC153328 
NM_001003938 HBM   NM_006953 UPK3A   NM_147164 CNTFR 
NM_001010887 ACER2   NM_006984 CLDN10   NM_152310 ELOVL3 
NM_001014980 FAM132A   NM_007056 SFRS16   NM_152331 ACOT4 
NM_001025290 DPPA5   NM_009586 SIM2   NM_152355 ZNF441 
NM_001025436 SPAG16   NM_012458 TIMM13   NM_152380 TBX15 
NM_001029864 KIAA1755   NM_013267 GLS2   NM_152640 DCP1B 
NM_001031734 FDX1L   NM_014037 SLC6A16   NM_153221 CILP2 
NM_001044370 MPPED1   NM_014350 TNFAIP8   NM_153230 FBXO39 
NM_001045476 WDR38   NM_014379 KCNV1   NM_153270 KLHL34 
NM_001063 TF   NM_014625 NPHS2   NM_153334 SCARF2 
NM_001080433 CCDC85A   NM_014898 ZFP30   NM_153449 SLC2A14 
NM_001080473 MFSD2B   NM_015356 SCRIB   NM_172057 KCNH2 
NM_001080509 TSPAN11   NM_015456 COBRA1   NM_172389 NFATC1 
NM_001085401 C6orf201   NM_015688 FAM184B   NM_173516 PNLDC1 
NM_001085480 FAM162B   NM_016002 SCCPDH   NM_173540 FUT11 
NM_001098517 CADM1   NM_016170 TLX2   NM_173547 TRIM65 
NM_001098519 LRRC43   NM_016463 CXXC5   NM_173560 RFX6 
NM_001103167 ZGLP1   NM_016529 ATP8A2   NM_173563 C6orf146 
NM_001111034 ACP5   NM_016564 CEND1   NM_175619 ZAR1 
NM_001115016 KIAA1310   NM_016592 GNAS   NM_177478 FTMT 
NM_001122636 GALNT9   NM_016831 PER3   NM_178861 RNF113B 
NM_001127612 PAX6   NM_017516 RAB39   NM_181689 NNAT 
NM_001127688 BEX4   NM_017614 BHMT2   NM_181723 EFHA2 
NM_001129895 HGC6.3   NM_017655 GIPC2   NM_181756 ZNF233 
NM_001130011 TEX101   NM_017767 SLC39A4   NM_182539 TCTE1 
NM_001134431 TOR2A   NM_017891 C1orf159   NM_183374 CYP26C1 
NM_001135197 CCDC36   NM_017918 CCDC109B   NM_198389 PDPN 
NM_001142575 IMPDH1   NM_018346 RSAD1   NM_198494 ZNF642 
NM_001142634 SPDYA   NM_018355 ZNF415   NM_198496 VWA2 
NM_001144382 PLCL2   NM_018467 USE1   NM_198537 YJEFN3 
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NM_001145030 C3orf77   NM_018487 TMEM176A   NM_198571 C7orf52 
NM_001145132 C5orf52   NM_018488 TBX4   NM_198580 SLC27A1 
NM_001145650 ZNF529   NM_018942 HMX1   NM_199037 SCN1B 
NM_001145657 RAP1GAP   NM_018951 HOXA10   NM_199054 MKNK2 
NM_001146054 SNCA   NM_018962 DSCR6   NM_199235 COLEC11 
NM_001159330 ARHGAP27   NM_019112 ABCA7   NM_201379 PLEC 
NM_001160226 CNR1   NM_020062 SLC2A4RG   NM_203425 C17orf82 
NM_001161625 NXNL2   NM_020134 DPYSL5   NM_206833 CTXN1 
NM_001164405 BHLHA9   NM_020404 CD248   NM_206860 TACC2 
NM_001166412 SMOC2   NM_020804 PACSIN1   NM_206894 ZNF790 
NM_001167676 LOC100128071   NM_021116 ADCY1   NM_207437 DNAH10 
NM_001172675 ZNF347   NM_021649 TICAM2   NR_001458 MIR155HG 
NM_001485 GBX2   NM_021831 AGBL5   NR_002781 TSPYL3 
NM_001801 CDO1   NM_022405 SLC6A20   NR_002814 LOC374443 
NM_002237 KCNG1   NM_022829 SLC13A3   NR_003366 ANKRD20B 
NM_002402 MEST   NM_023070 ZNF643   NR_004382 MESTIT1 
NM_002496 NDUFS8   NM_024017 HOXB9   NR_024349 LOC284023 
NM_002508 NID1   NM_024560 ACSS3   NR_024418 LOC389332 
NM_002531 NTSR1   NM_024600 TMEM204   NR_024523 LOC641367 
NM_002754 MAPK13   NM_024663 NPEPL1   NR_026807 C6orf155 
NM_003012 SFRP1   NM_024677 NSUN7   NR_026880 MGC12916 
NM_003253 TIAM1   NM_024718 C9orf86   NR_028334 FLJ40504 
NM_003269 NR2E1   NM_024857 ATAD5   NR_028343 ZNF415 
NM_003353 UCN   NM_025268 TMEM121   NR_028501 ECEL1P2 
NM_003550 MAD1L1   NM_030613 ZFP2   NR_029837 MIR219-2 
NM_004210 NEURL   NM_031909 C1QTNF4   NR_030638 MIR941-2 
NM_004324 BAX   NM_031925 TMEM120A   NR_030641 MIR943 
NM_004473 FOXE1   NM_031947 SLC25A2   NR_030646 MIR1225 
NM_004539 NARS   NM_032134 QRICH2   NR_031602 MIR1237 
            NR_031730 MIR1909 
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Discussion 
DREAM (Digital restriction enzyme analysis of methylation) is a recently developed 
methodology coupling specific amplification of fragmentized genomic DNA by restriction 
enzymes with the next-generation sequencing technology. This method has its distinct 
advantage to quantitatively measure the methylation levels of single CGs genome-widely due 
to paired usage of methylation-sensitive and methylation-insensitive restriction 
endonucleases (e.g. SmaI and XmaI for CCCGGG).  
On the other hand, the recognition site of CCCGGG restricts the representation of 
DREAM to certain locations. In human genome (Hg18), 11.76% of SmaI sites are in CGI 
and 61.81% are in various repeats. However, the access of endocleases to genomic areas of 
variable condensity would limit complete digestion, and size selection during library 
preparation must have caused loss of some fragments of over 500-bp length due to sparsely 
located SmaI sites. Additionally, it is not guaranteed by the sequencing platform that all of 
single molecules could be clustered and sequenced, because amplification process could not 
be avoided using next-generation sequencing. Therefore, instead of representing non-CGI or 
repeats, DREAM results obtained from four samples showed higher percentage of site 
coverage in CGIs and loss of information of repeats. Therefore, it would benefit our aim to 
study DNA methylation in CGI-promoters. 
From the datasets of significantly remethylated SmaI sites, we could infer two 
preferences of re-expressed DNMT3B in DKO cells. (1) CGIs, no matter whose locations 
are, were less vulnerable to DNA methylation; (2) Promoters which became demethylated 
were more resistant to DNMT3B. For the first one, the percentage of remethylated CGIs was 
less than that of remethylated non-CGIs, which, in some sense, was consistent with previous 
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findings about CGI-methylation. Also, the more immunity of promoters to remethylation 
proved the regulatory roles of transcription in recruiting and preventing DNA methylation.  
DNA methylation of CGIs at annotated TSSs (promoter) has different patterns from that of 
CGIs in gene bodies (intragenic) or between annotated genes (intergenic). In human and 
mouse genomes, about 70% annotated gene promoters have CGIs and almost half of CGIs 
have transcription starts whereas the other half are either inside or between transcription units 
(“orphan CGIs”) (134). Promoter-CGIs of normal cells are typically nonmethylated, possibly 
because the deposition of transcription factors can be facilitated by the higher frequency of 
CG presence which is contained in most transcription factor binding sequences (135), and/or 
the presence of RNAPII at CGIs is irrespective of gene activity (136). Other mechanisms are 
likely involved cooperatively in protecting CGIs from DNA methylation, such as active 
demethylation systems induced by Tet protein family (137, 138), and active chromatin marks 
(e.g. H3K4me3) which would interfere with DNMT activity (139). For “orphan CGIs” of 
normal cells, 17% of them have been shown methylated and intragenic CGIs have more 
tendency to become methylated (20%-45%) than intergenic CGIs (134, 140). The resistancy 
of some of them could result from active transcription of non-coding RNAs, or alternative 
splicing of genes in a manner dispensible of DNA methylation (141, 142). In contrast, 
cancers possess specific aberrant patterns of CGI-methylation, and genome-wide results have 
not shown distinct preferences of DNA methylation in promoter-CGIs, intragenic, or 
intergenic CGIs such as for colorectal cancers (134). But DNA methylation profiles 
suggested the resemblance of cancer-specific methylation styles and normal developmental 
patterns (143). 
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Our study of remethylation location does not diapprove any of the above findings, 
because quite a few genes are reactivated due to loss of memory of inhibition through 
cytosine demethylation (131). We are trying to uncover the properties of re-methylated sites 
using the baseline in DKO cells by the assumption that DNA methylation machinery in any 
cases complies with that in normal process.  
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Conclusions 
 
Our project is to identify the elements involved in triggering de novo DNA 
methylation of CGI-promoters. Considering epigenetic regulation would not work without 
the cooperation between cis-elements and trans-elements, we designed two kinds of 
strategies to investigate both aspects. One was to observe de novo methylation in transgenes, 
and the other was to see if there was preference for DNMTs.  
For the first strategy, we established a site-specific integration system that could 
allow comparison of several aspects in influencing de novo DNA methylation, specifically 
for CGI-promoters, under the same genomic background. The aspects of interest are (1) 
repetitive elements adjacent to CGI-promoters that are frequently hypermethylated in cancer 
cells; (2) the extent of transcriptional repression in regulating DNA methylation; (3) the 
effect of genomic position/cell line on DNA methylation. The system was constructed in two 
cancer cells with single integration sites to study the third aspect, and also a comparable cell 
lines with robust silencing induced by a defined transcriptional repressor were generated in 
parallel to study the second aspect. A set of fragments derived from two CGI-promoters (RIL 
and P16INK4A) surrounded by repetitive elements (SINE and LINE) were separately 
introduced into this system for the first aspect. We examined expression, DNA methylation 
and chromatin signatures of transgenes over a period of time, and found that (1) DNA 
methylation originates from certain CG sites within a LINE element; (2) methylation 
spreading into a promoter-CGI is facilitated by transcriptional repression, presence of 
additional repetitive elements and is site-specific; (3) transcriptional repression is required 
but not sufficient to promote DNA methylation. These observations are consistent with 
previous findings that DNA methylation serves as epigenetic locking step subsequent to gene 
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silencing. We further reveal that moderate gene silencing could not be sufficient for DNA 
methylation to occur, and triggering DNA methylation requires strong repression as well as 
additional influence via certain DNA sequence features, such as repetitive elements. The 
conclusion is described as a model in Figure 40.  
For the other strategy, we re-introduced DNMT3B into a characterized cell line, 
HCT116 DKO (DNMT1-/- DNMT3B-/-) to see the distribution of remethylated CG sites. By 
profiling genome-wide patterns of DNA methylation in HCT116, DKO and two clones with 
re-expressed DNMT3B, we were able to substract sets of CCCGGG sites either remethylated 
or un-remethyated when DNMT3B was present in DKO, and find that on the baseline of 
methylation in DKO, CGIs are less vulnerable for DNMT3B and promoters for most genes in 
DKO cells are more immune to remethylation. Combined together, CGI-promoters are, once 
again, shown not sensitive to DNA methylation.  
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Figure 39. A Model for late response of DNA methylation to transcriptional repression. 
(A) The promoter-CGI is protected from methylation by unknown mechanisms (“barriers”), 
while cytosines become methylated at neighbouring CG sites (“methylation center”) under 
moderate transcriptional repression. (B) Neither strong silencing nor presence of repetitive 
elements nearby can individually impose methylation spreading into the promoter-CGI, 
although strong silencing is able to enhance methylation center. (C) Both factors have to 
cooperate in order to overcome the “barrier” and facilitate CGI-methylation. 
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Significance and future directions 
 
CpG-Islands (CGIs) plays essential roles in regulation of gene transcription. More 
than half of annotated promoters in vertebrates are associated with CGIs, and quite a few of 
them belong to housekeeping genes, tissue-specific genes, tumor-suppressor genes and 
development-related genes (144). In normal cells, promoter CGIs are usually distinct due to 
lack of DNA methylation in vast contrast to the heavily methylated genomes. The specific 
mechanisms predisposing promoter CGIs against DNA methylation still remain unclear. 
There are several proposed elements involved in the process. First, the innate location of 
CGIs. Nearly half of CGIs are over TSSs (transcription start sites), and the rest are located 
between or within transcription units (134). CGIs oftern lack TATA box and are charaterized 
by hetergeneous TSSs, leading to dispersed transcription initiations and increasing the 
possibility for transcription factors to bind (145). In fact, genome-wide evidences have 
demonstrated higher CG contents of trancription factor binding sites or recognition sites 
(145). Second, boundary elements. It was observed factors like CTCF, Sp1 and USF1 could 
serve as barriers or enhancer blockers to prevent DNA methylation spreading from the 
adjacent regions. This has been well illustrated in the example of H19/Igf2 imprinting locus 
(54). Third, DNA demethylation of promoter-CGIs. The discoveries of active demethylases 
suggest another possibility of CGIs to resist DNA methylation. The ability of these enzymes 
to conver 5’-methylcytosines to 5’-hydroxymethyl-cytosines posed that the CGIs are under 
sporadic de novo methylation which would be quickly removed by these enzymes, like Tet1 
and Tet2. One domain of Tet1 is related with the CXXC-domain which was suggested to 
recognize CGIs, and recent findings further consolidated the directed demethylation by Tet1 
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to CGIs (137, 146). Fourth, characteristic chromatin signatures of promoter-CGIs. The active 
marks, H3K4me3 and histone acetylation, stands particularly for active transcription, which 
have long been indicated with inverse correlation with DNA methylation. While even with 
repressive marks, the CGIs may not always the accompanied features of silenced CGIs. 
Either DNA methylation occurs slower than the enrichment for inactive marks (84), or would 
not appear at all (112).   
In our experiments, we do not have sufficient evidences to prove any of the above 
protection mechanisms, but rather we are aiming to first investigate possible participants for 
methylation spreading into CGIs. In the site-specific integration system used here, we 
manipulated exogenous fragments, transcriptional strength, integration sites and/or cell lines, 
and found that significant CGI-methylation may have to achieve seeded DNA methylation at 
adjacent sites. Methylation spreading could become apparent once the structural features and 
the transcription activity of CGI-promoters had established a local environment facilitating 
the access of DNMTs to CGIs. In this sense, not every promoter-CGIs are under the same 
chances to be sensitive to DNA methylation. Therefore, as illustrated in figure 39, inactive 
transcription could be easily reverted, while under the permission of sequence features 
together with strong repression, once DNA methylation significantly occurs within CGIs, 
gene silencing would be locked and propagated to the next few generations through semi-
conservative inheritance of DNA methylation. Furthermore, we would infer that the variable 
patterns of DNA methylation in normal and abnormal development may be predetermined by 
gene structures, and also reflect the upstream signaling during the early time points.  
However, the conclusions drawn from our experiments must be testified by further 
studies. Using the same site-specific integration system, we could expand the objects in order 
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to test the appliability of our conclusions. (1) exogenous fragments from other repetitive 
elements, either active or inactive, could be included; (2) instead of tetO and tTS, other 
transcription factors and respective binding/recognition sites could be compared in parallel; 
(3) more cell lines and integration sites could be constructed.  
Our studies of cis-regulatory and trans-regulatory aspects for de novo DNA 
methylation would facilitate our understanding of methylated genes which are less sensitive 
to epigenetic drug treatment. Because if genes are robustly silenced by transcription factors 
like tTS, part of which is derived from zinc-finger proteins, and possess a very condensed 
local chromatin conformation, although their CGIs are methylated, treatments with 
epigenetic drugs (TSA or DAC) would possibly not be capable of making local chromatin 
decondensed enough for gene reactivation. If these genes are critical for reverting cancer cell 
destiny, then epigenetic drugs could not prevent relapse by only recovering partial epigenetic 
profiles. In our experiments, we observed the inability of TSA or DAC to reactivate 
transgenes with enforced transcriptional repression by tTS, thereby the above possibility 
could exist. Thus, if such situations influence therapeutical outcomes, further profiling 
insensitive genes and identification of new chemical would be necessary.  
We have already found that both cis- and trans- regulatory aspects are necessary for de 
novo DNA methylation. However, it is still unclear what the common features of the cis-
squences are for de novo methylation, and what kinds of chromatin signatures predetermine 
DNA methylation. In order to investigate these questions, further studies could be applied: 
(1) Genome-wide analysis of histone marks (H3K4me3, H3K27me3 and H3K9me3) in 
HCT116, DKO and DKO/DNMT3B clones by ChIP-seq. Combined with gene 
expression profiles by microarrays and DNA methylation profiles obtained by 
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DREAM, the pre-existent features of transcription and epigenetics could be identified 
for genes/regions sensitive or refractory to DNA methylation.  
(2) The above datasets could also be combined with publicly available information of 
binding motifs for various transcription factors or enzymes to obtain cis-signals for 
DNA methylation. 
(3) On the other hand, the identified sequence features could be introduced into the site-
specific system used in this project for functional validation.   
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